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Thrombosis is the formation of a blood clot that obstructs the blood flow through the 
circulatory system. Thrombosis can occur in veins and arteries. In the 19th century, Rudolf 
Virchow described the three factors necessary for the formation of thrombosis: blood 
stasis, changes in the vessel wall and hypercoagulability (1). While Virchow was referring 
to venous thrombosis, the same processes have been observed in arterial thrombosis. 
Both diseases have long been considered as separate entities, partly due to differences in 
mechanistic pathways as well as their distinct clinical presentation. Venous thrombosis 
occurs under low shear flow conditions due to alteration of blood stasis and composi-
tion, and is fibrin-rich due to the large amount of red blood cells (figure 1) (2). Unlike 
venous thrombosis, arterial thrombosis occurs under high shear flow due to formation 
of platelet-rich thrombi around ruptured atherosclerotic plaques and damaged vascular 
endothelium. Venous thrombosis might lead to venous thromboembolism (VTE), while 
arterial thrombosis causes myocardial infarction and ischemic stroke. Traditional risk 
factors of venous thrombosis (e.g. surgery, immobilization and cancer) also differ from 
those that are associated with arterial thrombosis (e.g. smoking, obesity and diabetes). 
The separate nature of venous and arterial thrombosis has, however, been challenged 
by numerous reports, suggesting a closer link between both diseases (3-5).
The perceived difference between venous and arterial thrombosis is also reflected in 
the antithrombotic management. Oral anticoagulation is considered first-line treatment 
in fibrin-rich venous thrombi, whereas antiplatelet therapy is regularly recommended in 
platelet-rich arterial thrombi. Importantly, the use of antithrombotic drugs is associated 
with an increased risk of bleeding that potentially results in high risk of morbidity and 
mortality. Therefore, when deciding on antithrombotic treatment, the risk of thrombosis 
Low shear ow High shear ow
brin platelet red blood 
cell macrophage
Venous thrombosis Arterial thrombosis
endothelial 
cell
figure 1. Pathophysiological differences between arterial and venous thrombosis. Figure adapted from 
Koupenova et al. (2017) (2)
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should be equally weighed against the risk of bleeding. The appropriate antithrombotic 
treatment remains challenging and still has many grey areas. Importantly, both diseases 
are currently the leading causes of death in the Western parts of the world (6).
The first part of this thesis discusses VTE. For the individual patient, the risk of fatal 
recurrent VTE versus that of fatal bleeding is of particular relevance when deciding on 
the duration of therapeutic management. In chapter 2, the mortality risk of recurrent 
VTE is demonstrated after anticoagulation cessation in patients with initially unpro-
voked VTE. So far, these exact numbers were unknown for patients with unprovoked 
VTE, even though this knowledge is especially valuable for this specific patient category 
because of the recommendation for indefinite treatment duration, while patients with 
provoked VTE are generally treated for a short period of time (7, 8). Furthermore, VTE 
is frequent complication of cancer and cancer treatment (9). International guidelines 
currently recommend low-molecular-weight heparin (LMWH) therapy as first-line treat-
ment because of a lower recurrence risk compared to the traditional therapy with vita-
min K antagonists (VKA) (10). However, these daily subcutaneous LMWH injections may 
be burdensome owing to local pain or bruising, allergic reactions, or heparin-induced 
thrombocytopenia. In chapter 3, we prospectively assessed the discontinuation rate of 
these daily injections. The aim of chapter 4 was to compare the discontinuation rate 
between two commonly used LMWH compounds – enoxaparin and nadroparin – in the 
same patient cohort as chapter 3.
The topic of the second part comprises prevention of arterial thrombosis after heart 
valve surgery. In patients undergoing bioprosthetic aortic heart valve implantation or 
mitral valve repair, patients are at risk of thromboembolism (11, 12). The optimal anti-
thrombotic therapy after both procedures is still a matter of controversy. In chapter 5 
and chapter 6 the rates of thromboembolic and bleeding complications are evaluated 
of two antithrombotic prevention strategies - VKA and aspirin - after bioprosthetic aortic 
valve implantation and mitral valve repair respectively.
The last part of the thesis focuses on idarucizumab for urgent dabigatran reversal. 
Dabigatran is a direct thrombin inhibitor that has a favorable risk-benefit profile com-
pared to VKA for the prevention of ischemic stroke in patients with non-valvular atrial 
fibrillation and treatment of patients with venous thromboembolism (13, 14). However, 
the lack of a reversal agent often has been considered as a hurdle for prescribing dabiga-
tran. This has prompted the recent development of specific reversal agent idarucizumab 
for urgent dabigatran reversal in patients with uncontrolled or life-threatening bleeding 
or undergoing an emergency procedure (7). Because data on idarucizumab are scarce, 
chapter 7 was aimed to determine the appropriateness of its usage as well as the he-
mostatic effectiveness and clinical outcome in daily practice. In chapter 8, dabigatran 
reversal by idarucizumab is discussed in patients presenting with major gastrointestinal 
(GI) bleeding, as evaluated in the RE-VERSE AD study (15).
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abSTRaCT
Current guidelines recommend long-term anticoagulant therapy in patients with unpro-
voked venous thromboembolism (VTE). The risk of fatal recurrent VTE after treatment 
discontinuation (versus that of fatal bleeding during anticoagulation) is of particular rel-
evance in the decision to continue or stop anticoagulation after the first three months. 
Our primary aim was to provide a point-estimate of the yearly rate of fatal recurrent VTE 
and VTE case-fatality rate in patients with unprovoked VTE after anticoagulation ces-
sation. Data were extracted from both randomized controlled trials and observational 
studies published before May 1st 2017. The pooled fatality rates were calculated using 
a random-effects model. Eighteen studies with low to moderate bias were included in 
the primary analysis, totaling 6758 patients with a median follow up duration of 2.2 
years (range 1-5 years). After anticoagulation cessation, the weighted pooled rate of VTE 
recurrence was 6.3 (95% CI 5.4-7.3) and the weighted pooled rate of fatal recurrent VTE 
was 0.17 (95% CI 0.047-0.33) per 100 patient-years, for a case-fatality rate of 2.6% (95% 
CI 0.86-5.0). These numbers are a solid benchmark for comparison to the risks associated 
with long-term anticoagulation treatment for the decision on the optimal duration of 
treatment of patients with unprovoked VTE.
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InTRoduCTIon
The risk of recurrent venous thromboembolism (VTE), which includes deep vein throm-
bosis (DVT) and pulmonary embolism (PE), persists after cessation of anticoagulant 
treatment and is particularly high among patients with unprovoked VTE (1-3). Conse-
quently, recent treatment guidelines recommend continuation of anticoagulant therapy 
beyond the first three months in patients with unprovoked VTE without high risk for 
major bleeding (4-6). This recommendation is based on weighing the risk of recurrent 
VTE after anticoagulant treatment cessation against the risk of major bleeding during 
ongoing treatment. For the individual patient, the risk of fatal recurrent VTE versus that 
of fatal bleeding is of particular relevance when making the decision to prolong treat-
ment or not.
The case-fatality rate of major bleeding events during long-term vitamin K antago-
nist (VKA) treatment has been estimated to be as high as 9%-13%, with a yearly rate 
of fatal bleeding varying between 0.2% and 1.5% (7, 8). Importantly, this bleeding risk 
was found to decrease considerably with the introduction of direct oral anticoagulants 
(DOACs) that are associated with lower rates of intracranial and fatal bleeding than VKA, 
while non-inferiority was shown with regard to risk of recurrent VTE (9).
The case-fatality rate of recurrent VTE after cessation of anticoagulant therapy has 
previously been shown to vary between 3.6% and 5.1% in a mixed cohort of patients 
with both provoked and unprovoked VTE, with a yearly risk of fatal recurrence ranging 
between 0.4% and 0.5% (7, 10). To date, these exact numbers are unknown for patients 
with unprovoked VTE, although this is the patient category for which this knowledge is 
most relevant (4, 5). Therefore, we conducted a systematic review and meta-analysis of 
the literature to provide an accurate point-estimate of the case-fatality rate of recurrent 
VTE as well as a yearly rate of fatal recurrences after anticoagulation cessation in patients 
with a first unprovoked VTE.
MeThodS
data sources and literature search
A systematic literature search was conducted for all relevant publications in PubMed, 
Embase, Web of Science and Cochrane in May 2017. The Subject Headings and/or 
keywords of our search strategy comprised ‘Venous Thromboembolism’, ‘Pulmonary 
Embolism’, ‘Deep Venous Thrombosis’, ‘Anticoagulation’ and ‘Recurrence’ and were 
database-specifically translated (Supplementary Appendix).
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Study selection and data extraction
Initial results were screened for relevant titles and abstracts by two independent 
reviewers (S.J. and L.M.). This process was performed in duplicate and disagreements 
were independently resolved by consensus or by a third reviewer (F.A.). Studies were 
included if: i) consecutive patients with objectively confirmed symptomatic DVT or PE 
were prospectively enrolled (proximal DVT diagnosed in case of evidence of thrombosis 
in the popliteal or more proximal veins on compression ultrasonography or contrast 
venography and a diagnosis of PE based on at least one subsegmental filling defect 
on computed tomography pulmonary angiography (CTPA), high-probability ventila-
tion perfusion lung scan (V/Q) or abnormal pulmonary angiography, (ii) patients were 
dedicatedly followed for symptomatic recurrent VTE and such events were objectively 
confirmed, (iii) the initial anticoagulation treatment (with VKA or DOAC) was continued 
for at least three months and the follow-up period extended for at least three months 
after the anticoagulation therapy was discontinued, (iv) fatal VTE events during follow-
up after treatment cessation were reported (PE and/or DVT) and (v) at least 100 patients 
were included. Only full-text publications in the English language were reviewed for 
potential inclusion. There was no restriction on publication year.
After selection of all relevant articles, two reviewers (S.J. and L.M.) independently 
extracted data on first author’s name, year of publication, design (prospective/retro-
spective), number of patients included, age, initial anticoagulation treatment, the total 
duration of follow up after cessation of treatment, proportion of unprovoked VTE at 
baseline (PE/DVT), case-fatality rate of recurrent VTE during follow-up after anticoagu-
lant discontinuation (PE/DVT) and finally overall mortality during follow-up, as reported 
by the authors. The authors of publications with missing data were approached by email 
at least two times on two weeks apart. The PRISMA statement for reporting systematic 
reviews and meta-analysis was used for this study (12).
Study objectives
The primary objective was to determine the case-fatality rate of recurrent VTE after 
anticoagulation cessation following a first unprovoked VTE diagnosis, as well as the 
yearly rate of fatal VTE recurrences from selected studies with low to moderate bias. 
The secondary aims were to determine the overall rate of fatal VTE for all available stud-
ies, including those with a high risk of bias, and to differentiate between: i) enrolment 
periods, comparing studies that started enrolment before and after the 1st of January 
2000 (if reported), ii) cohort studies and RCTs, iii) studies with a follow-up duration that 
was shorter versus longer than 2.5 years, iv) patients who initially presented with DVT 
versus unprovoked PE and v) different definitions of fatal VTE that were applied.
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Study outcomes and definitions
Recurrent PE was predefined as a new intraluminal filling defect on pulmonary an-
giography or CTPA, a new high probability perfusion defect on V/Q scan or any new 
defects after earlier normalisation of the scan (11). Recurrent DVT was defined as new 
non-compressibility by ultrasonography of the common femoral and/or popliteal vein, 
non-compressibility of a previously normalised vein segment, or a pronounced increase 
in vein diameter (≥ 4 mm) of a previously non-compressible venous segment (11). Pa-
tients with both index DVT and PE were classified as patients with PE when fatal rates 
were reported separately for this subgroup. Fatal recurrent VTE was predefined as PE 
diagnosed by autopsy, high-probability V/Q scan, a new intraluminal filling defect de-
tected on pulmonary angiography, computed tomography (CTPA) or venography prior 
to death, or a high clinical suspicion as judged by the investigators of the individual 
studies. For each study, the definition of unprovoked VTE was evaluated post-hoc and 
compared to criteria provided by the Scientific and Standardization Committee of the 
International Society on Thrombosis and Haemostasis (13).
Risk of bias
Two authors (S.J. and L.M.) independently evaluated the risk of bias at a study level in 
accordance with the Cochrane Collaboration’s tool for assessing risk of bias and the 
PRISMA statement (12, 14). We focused on the following criteria: 1) pre-specified proto-
col, 2) clear description of inclusion and exclusion criteria, 3) adequate anticoagulation 
treatment prior to cessation according to international standards, 4) clear description of 
follow-up after anticoagulation cessation, 5) clear definitions provided of unprovoked 
and fatal VTE, 6) loss to follow up, 7) adjudication of outcomes, and 8) assessment of 
primary endpoint in all patients. Disagreements were resolved through discussion with 
a third author (F.A.).
Statistical analyses
Case-fatality rates of each study were calculated by dividing the number of recurrent 
fatal VTEs by all recurrent VTEs. The case-fatality rates were pooled after Freeman-Tukey 
double arcsine transformation to stabilize variances, using a random effects model 
according to the method of DerSimonian and Laird (15, 16). Pooled case-fatality rates 
were reported with corresponding 95% confidence intervals (CIs). Subsequently, we 
estimated the rate of recurrent VTE and fatal recurrent VTE per 100 patient-years. We 
assessed statistic heterogeneity of exposure effects across the various cohort studies 
by calculating the I2 statistic, which depicts the variance of results from study to study 
beyond (or rather than) chance. Heterogeneity was considered low when I2 was <25%, 
intermediate when I2 was 25–75% and high when I2 was >75% (17). Heterogeneity was 
explored using meta-regression. We evaluated differences across subgroups under the 
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null hypothesis of no differences (χ2 distribution with S (number of subgroups) minus 1 
degree of freedom). All analyses were performed using Stata 14.0 (Stata Corp., College 
Station, TX, USA).
ReSuLTS
Literature search and study selection
The initial search yielded 7647 potentially relevant articles; 586 in Cochrane, 2839 in 
EMBASE, 2307 in PubMed and 1915 in Web of Science (figure 1). After the first screen-
ing of title and abstract, 7540 records were excluded, leaving 107 unique articles for 
detailed assessment. An additional 83 articles were excluded after full review for the 
following reasons: 28 were abstracts only, with insufficient information, 27 comprised 
studies of duplicate patients with other reports, eight did not clarify if fatal events were 
on or off anticoagulation treatment, eight had fewer than 100 patients, four did not dis-
tinguish between provoked and unprovoked VTE and authors did not comply with our 
data request after at least two attempts, and eight were excluded for other reasons. The 
remaining 24 articles all satisfied our predetermined methodological criteria (18-41).
figure 1. Flow-chart of the clinical search
* 6 Duplicates van uitgebreide analyse erbij geteld




 Web of Science: 1915
Excluded (n=7540) 
 Duplicates (n=2431)
 Not relevant based on title and abstract (n=5109)
Detailed assessment for eligibilty (n=107)
Excluded (n=83)
 Abstracts without sucient information (n=28) 
 Duplicate patients (n=27)
 Unclear if fatal events were on or o treatment (n=8)
 Fewer than 100 patients included (n=8)
 No distinction between provoked and unprovoked VTE (n=4)
 Other reasons (n=8)
Included for analysis (n=24) 
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Included studies
Table 1 shows the characteristics of the included studies. Fifteen were cohort studies 
(21, 23-26, 28, 29, 32, 33, 35, 37-41) and nine were RCTs (18-20, 22, 27, 30, 31, 34, 36). 
The 24 articles were published between 1995 and 2017 and included a total of 8914 
patients with unprovoked VTE (range 117-914 patients per study). The median follow-up 
duration after treatment cessation was 2.5 years (range 1-7.7 years). The evaluation of 
the presence of bias is shown in Table 2. Of the 24 studies, 18 were considered to be at 
low or moderate risk of bias and were included in the primary analysis. Five studies did 
not involve an independent adjudication committee (24, 28, 32, 33, 40). Most studies did 
not meet the criteria of the ISTH definition of unprovoked VTE (20, 21, 24, 26, 28-30, 32, 
34-39, 41). One study did not provide a definition of unprovoked VTE at all (22).
Primary outcome: rate of fatal recurrent VTe in studies with low or moderate 
risk of bias
The 18 studies with low or moderate risk of bias enrolled a total of 6758 patients with 
a median follow up of 2.2 years (range 133-914). Table 3 shows the rates of recur-
rent VTE and fatal recurrent VTE per subgroup. The weighted pooled rate of recurrent 
VTE in studies with low or moderate risk of bias was 6.3 (95% CI 5.4-7.3; I2=72.6%) 
per 100 patient-years and the rate of fatal recurrent VTE was 0.17 (95% CI 0.047-0.33; 
I2=83.57%) per 100 patient-years, for a case-fatality rate of 2.6% (95% CI 0.86-5.0; I2: 
66.6%; figure 2).
Secondary outcomes
The overall weighted pooled fatal rate of VTE recurrence among all 24 studies was 6.2 
(95% CI 5.4-7.2; I2=86.8%) per 100 patient-years and the rate of fatal recurrent VTE was 
0.13 (95% CI 0.036-0.25; I2=72.7%) per 100 patient-years, for a case-fatality rate of 2.0% 
(95% CI 0.69-3.8; I2: 65.2%; Supplementary appendix, figure S1).
Studies that initiated enrolment before the year 2000 had a numerical higher but not 
significant different pooled rate of fatal VTE than studies that started inclusion within 
or after the year 2000 (0.27, 95%CI 0.038-0.59; I2=83.1 vs. 0.039, 95%CI 0.0028-0.1 per 
100 patient-years; I2=0; P=0.70 for interaction), as well as case-fatality rate (3.7%, 95%CI 
0.95-7.6; I2=76.5 vs 0.71%, 95%CI 0.063-1.8; I2=0; P=0.21 for interaction; Supplementary 
appendix, figure S2). Notably, the analysis of the more recent studies showed good 
homogeneity (both I2=0) while the results of earlier studies were quite heterogeneous 
(I2>75). The rate of fatal recurrent VTE was similar in cohort and RCT studies (0.11, 95% CI 
0.009-0.29; I2=79.5% vs. 0.14 95% CI 0.021-0.33; I2=49.7% per 100 patient-years; P=0.96 for 
interaction) and studies with short and longer than 2.5 years follow up duration (0.11, 95% 
CI 0.018-0.27; I2=52.4% vs. 0.13, 95% CI 0.076-0.35; I2=81.7% per 100 patient-years; P=0.94 
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Schulman et al., 1995 [18] • • • • • • • • •
Agnelli et al., 2001 [19] • • • • • • • • •
Ridker et al., 2003 [20] • • • • • • • • •
Baglin et al., 2003 [21] • • • • • • • • •
Schulman et al., 2003 [22] • • • • • • • • •
Cosmi et al., 2005 [23] • • • • • • • • •
Young et al., 2006 [24] • • • • • • • • •
Prandoni et al., 2007 [25] • • • • • • • • •
Baglin et al., 2008 [26] • • • • • • • • •
Prandoni et al., 2009 [27] • • • • • • • • •
Poli et al., 2010 [28] • • • • • • • • •
Siragusa et al., 2011 [29] • • • • • • • • •
Becattini et al., 2012 [30] • • • • • • • • • 
Brighton et al., 2012 [31] • • • • • • • • •
Olie et al., 2012 [32] • • • • • • • • •
Ribeiro et al., 2013 [33] • • • • • • • • •
Schulman et al., 2013 [34] • • • • • • • • •
Galanaud et al., 2014 [35] • • • • • • • • •
Couturaud et al., 2015 [36] • • • • • • • • •
Kearon et al., 2015 [37] • • • • • • • • •
Rodger et al., 2016 [38] • • • • • • • • •
Kyrle et al., 2016 [39] • • • • • • • • •
Moreno et al., 2016 [40] • • • • • • • • •
Rodger et al., 2017 [41] • • • • • • • • •
note: VTE=Venous Thromboembolism
Overall Definition unprovoked/fatal VTE Overall risk of bias
 • unknown or unclear  • other than definitions in our study • high risk
 • no  • not present • moderate risk
 • yes  • according to definitions in our study • low risk
Patient population: patient selection
 • no distinction in follow up and baseline characteristics between provoked and unprovoked VTE
 • no distinction in follow up or baseline characteristics between provoked and unprovoked VTE
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(1.7%, 95% CI 0.19-4.2; I2=74.6% vs. 2.5%, 95% CI 0.69-5.0; I2=26.8%; P=0.87 for interac-
tion) as well as for studies with shorter and longer than 2.5 years follow up duration 
(2.2%, 95% CI 0.22-5.4; I2=76.6% vs. 1.8%, 95% CI 0.46-3.8; I2=34.9%; P=0.69 for interac-
tion).
In 19 studies, fatal recurrent VTE could be distinguished for patients initially present-
ing with DVT versus PE (13, 18, 19, 23-25, 27-39, 41). The case-fatality rates of patients 
initially presenting with DVT and PE were 2.3% (95% CI 0.52-4.8; I2=60.39%) and 0.12% 
(95% CI 0-1.8; I2=34.9%; P=0.57 for interaction; Supplementary appendix, figure S3). 
When focussing on studies with low or moderate risk of bias only, this numerically dif-
ference decreased considerably (2.7% (95% CI 0.50-6.1; I2=63.52%) versus 1.6% (95% CI 
0-5.7; I2=48.43%); P=0.66 for interaction; Supplementary appendix, figure S4).
fatal VTe definition
The definition of fatal VTE varied widely across studies (Supplementary appendix, 
Table S1). Only twelve studies (54%) actually reported a definition of fatal VTE (18, 19, 22, 
24, 25, 27, 30, 31, 34, 36-38), of which eleven (92%) included autopsy and/or clinical sus-
figure 2. Meta-analysis of the case-fatality incidences after anticoagulant cessation in studies with low to 
moderate risk of bias.
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picion (18, 19, 22, 24, 25, 27, 30, 31, 36-38) and five (42%) involved ‘sudden unexplained 
death’ (25, 27, 34, 36, 37). Studies including ‘sudden unexplained death’ in their fatal VTE 
definition were found to have the highest case-fatality rates (3.6%, 95% CI 0.018-11; I2= 
81.15%), while studies without a clear definition of fatal recurrent VTE reported lowest 
rates (0.95%, 95% CI 0.067-2.5; I2= 27.06%; P=0.29 for interaction) Supplementary ap-
pendix, Table S2). This difference in case-fatality rates was observed in both index PE 
and index DVT patients.
dISCuSSIon
In this systematic review and meta-analysis, we determined the risk of fatal recurrent 
VTE in patients with unprovoked VTE after cessation of anticoagulation treatment. 
We observed a pooled rate of fatal recurrent VTE of 0.17 per 100 patient-years with a 
case-fatality rate of 2.6% in studies with low to moderate risk of bias. Where most meta-
analyses performed in our study showed relevant heterogeneity among the included 
studies, the secondary analysis focussing on more recent studies (patient enrolment 
after January 1st 2000, total of 4508 patients) showed good homogeneity. The numeri-
cally lower pooled rate of fatal recurrence (0.039 per 100 patient-years) and case-fatality 
rate (0.71%) found in this subanalysis may be explained by improved patient care over 
the years, earlier presentation at the hospital or detection of smaller and less dangerous 
PE blood clots by more advanced CTPA technology.
The present study revealed similar rates of fatal recurrent VTE in cohort studies com-
pared to RCTs, thus supporting the external validity of our findings. The fatal rates of 
studies with longer and shorter follow-up durations did not differ as well, indicating that 
our main finding is valid for long-term follow-up (at least beyond the first two years after 
treatment continuation). Further, we use the finding of a lower rate of fatal recurrent VTE 
in more recent studies as an argument to hypothesize that the identified rates in our 
main analysis represent an overestimation of the ‘true’ risk rather than an underestima-
tion. Therefore, our findings provide clinicians, guidelines committees, investigators and 
policymakers with a solid and valid benchmark of the mortality risk due to recurrent 
VTE after cessation of treatment to be compared with the risks associated with long-
term anticoagulation treatment for patients with unprovoked VTE (4, 5). Importantly, 
since risk of VTE recurrence changes over time with the bulk of recurrences occurring in 
the first years, and the risk of bleeding remains more stable, the ultimate answer to the 
question of the most optimal duration of anticoagulation for unprovoked VTE is to be 
determined in future RCTs with long-term follow-up.
We found a non-significant higher risk of fatal recurrent VTE after an index DVT diag-
nosis than after an index PE diagnosis which was unexpected (7, 10). This difference is 
Fatal recurrent VTE after anticoagulation cessation 27
mostly explained by biases of the data pooling due to major methodological differences 
between the included studies. Other explanations may be that PE is often over diagnosed 
due to adoption of more and more advanced CT technology (42). In addition, a selection 
of ‘healthier’ PE patients for whom anticoagulation discontinuation was deemed to be 
safe in observational studies could have contributed to the lower observed fatal rates of 
recurrent VTE. Lastly, many of the patients with DVT may actually have had PE as well, 
although this was not objectively confirmed and therefore nor reported in the original 
study publications.
Remarkably, the reported rate of fatal recurrent VTE was largely dependent on the 
definition adopted across the various studies. Overall, studies without a clear definition 
reported the lowest rates, whilst studies in which unexplained death was adjudicated 
as recurrent VTE showed the highest rates. Half of the included studies did not report a 
definition of fatal VTE, whereas the remaining studies used various definitions ranging 
from autopsy findings alone to ‘sudden unexplained death’. With no widely accepted 
definition of ‘fatal VTE’, it is impossible to rank these different definitions, although it 
seems reasonable to assume that studies focussing on autopsy findings may provide 
underestimated rates of fatal recurrent VTE, while the opposite is true for studies ad-
judicating all unexplained death as being provoked by recurrent VTE. Moreover, the 
adjudication process itself might also be difficult and could possibly lead to different 
rates of PE-related deaths among studies. Our findings thus urgently call for an effort 
to standardize this definition for future studies in order to allow for valid inter-study 
comparisons (43).
Current guideline recommendations with regard to extended duration of treatment 
after unprovoked VTE will be confirmed beyond doubt if these studies show that long-
term treatment with DOACs is, indeed, associated with a yearly rate of fatal bleeding 
lower than 0.047-0.33%. Until then, anticoagulation duration should be individualised 
based on a patient-specific balance between bleeding and recurrent thrombotic risk. 
Valid bleeding and thrombotic risk tools have been developed and -although not vali-
dated in RCTs- could be helpful to assess these risks and thereby identify patients who 
may benefit from short or long-term anticoagulation treatment (44-47).
Strong points of this analysis include the strict selection criteria applied and the large 
number of patients studied. Source data were only derived from high-quality studies. 
Moreover, we were able to compare fatal rates in four relevant subgroups. Our study has 
several limitations in addition to the issue of varying definitions of fatal recurrent VTE. 
In particular, we did not have the availability of patient-level data, which would have 
allowed us to evaluate the prognostic role of risk factors such as age and gender. Also, 
although we performed rigorous inclusion criteria and focused only on high-quality 
studies, the meta-analyses presented were subject to relevant heterogeneity caused by 
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several between-study differences, especially for those studies that enrolled patients 
before January 1st 2000.
Conclusions
This meta-analysis revealed a pooled rate of fatal recurrent VTE of 0.17 (95% CI 0.047-
0.33) per 100 patient-years for patients with unprovoked VTE after discontinuation of 
anticoagulation therapy in studies with low to moderate risk of bias. This was consistent 
with a case-fatality rate of 2.6% (95% CI 0.86-5.0). Notably, we observed utilisation of 
varying fatal VTE definitions which was associated with moderate to high between-study 
heterogeneity, affecting the reported rates of fatal recurrent VTE. Current guideline rec-
ommendations on the duration of treatment of unprovoked VTE would be strengthened 
if future studies show that long-term anticoagulation treatment with DOACs is indeed 
associated with a rate of fatal bleeding lower than 0.33% per year, representing the up-
per limit of the 95% confidence interval the pooled incident rate of fatal recurrent VTE 
after anticoagulation discontinuation.
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Current guidelines recommend low-molecular-weight-heparins (LMWH) monotherapy 
for 3 to 6 months as first-line treatment for cancer-associated venous thromboembolism 
(VTE). However, although daily administration of LMWH injections over a course of sev-
eral months may be burdensome, the number of patients who quit because of LMWH 
side effects is unknown.
objectives
The aim of this study was to evaluate the continuation rate and complications of daily 
LMWH injections in cancer-associated VTE.
Methods
Consecutive patients with active cancer and objectively confirmed symptomatic 
proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE), treated at three 
Dutch hospitals and one Spanish hospital, were included to evaluate adherence to 
LMWH therapy during LMWH treatment. Patients were excluded when they received 
other anticoagulants, were lost to follow up or experienced a venous catheter-associated 
thrombosis.
Results
A total of 372 patients were analysed during LMWH treatment with a maximum of 180 
days. The cumulative incidence of discontinuation was 21% (95% confidence interval 
(CI): 17-25) after a median period of 90 days (interquartile range 60-120 days). Only 
female sex was found to be significantly associated with premature LMWH discontinua-
tion (OR 1.6; 95%CI 1.03-2.5). Thirty patients (8.1%) developed recurrent VTE, 30 patients 
(8.3%) suffered a major bleeding and 106 patients (28%) died.
Conclusion
Our study reveals that one out of five patients with cancer-associated VTE stopped 
LMWH injections because of side effects. This finding provides relevant background 
information to current clinical trials investigating the efficacy and safety of direct oral 
anticoagulants (DOACs) compared to LMWH.
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InTRoduCTIon
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pul-
monary embolism (PE), is a frequent complication of cancer and cancer treatment 
(1). Moreover, the treatment of cancer-associated VTE is challenging because cancer 
patients display a substantially high risk of recurrent VTE as well as major bleeding 
complications (2, 3).
Low-molecular-weight heparins (LMWH) are recommended for at least three to six 
months as first-line treatment for cancer-associated VTE by most current international 
guidelines because of proven superior efficacy compared to conventional vitamin K 
antagonists (VKA), with comparable risk of major bleeding (4-6). Treatment with LMWH 
consists of daily subcutaneous self-injections, often in an ambulatory setting. Admin-
istration of LMWH therapy over a course of several months may be burdensome due 
to local pain or bruising linked to the subcutaneous injection allergic reactions, or less 
frequently heparin-induced thrombocytopenia. Pain and skin hematoma at the injec-
tion site are the most common adverse side effects in daily practice, occurring in up to 
90% of subjects with self-administration (7). Studies investigating the efficacy of long-
term LMWH use in cancer patients found discontinuation rates varying from 33% to 58% 
after three to six months, because of complications including recurrent VTE, bleeding 
or death (8-10). Further, in recent studies 11% to 20% of cancer patients switched from 
LMWH injections to oral anticoagulants within three to six months, possibly due to avoid 
discomfort of injections or due to a lack of communication among health professionals 
or a deliberate physician’s decision (11-13). Thus, detailed information about the burden 
of daily subcutaneous injections is required.
More accurate knowledge of the tolerability of long term use of LMWH in cancer pa-
tients with VTE is very relevant when considering optimal management of this specific 
patient category, in particular with the advent of the direct oral anticoagulants (DOACs) 
that may offer a more attractive treatment option (14). We set out an observational 
study to evaluate the continuation rate and complications of daily LMWH injections in 
cancer patients with VTE in daily clinical practice.
MeThodS
Patients
This was a prospective, multi-center, cohort follow-up study of consecutive patients 
with active cancer and objectively confirmed symptomatic proximal DVT and/or PE 
to evaluate adherence to LMWH therapy during LMWH treatment with a maximum of 
180 days. Patients from three Dutch hospitals (Leiden University Medical Center, Alrijne 
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Hospital Leiden and Leiderdorp) and one Spanish Hospital (Ramon y Cajal Hospital, 
IRYCIS) diagnosed with cancer-associated VTE between 2004 and 2014 and treated with 
therapeutic doses of LMWH were eligible for inclusion. We defined active cancer in ac-
cordance with previous studies on this subject (4): a histologically confirmed solid tumor 
or hematological malignancy diagnosed or treated during the previous six months, 
recurrent or metastatic cancer, or cancer in palliative stages with the exception of basal 
cell or squamous-cell carcinoma of the skin.
Proximal DVT was diagnosed in case of evidence of thrombosis in the popliteal or 
more proximal veins on compression ultrasonography or contrast venography (15). A 
diagnosis of PE was based on at least one subsegmental filling defect on computed 
tomography pulmonary angiography (CTPA), high-probability ventilation perfusion 
lung scan or abnormal pulmonary angiography (15). In the LUMC and Alrijne Hospital 
patients were treated with weight-adjusted doses of subcutaneous nadroparin, either 
given once or twice daily - Fraxodi was given by 11,400 IU once daily (OD) for patients 
under 70 kg and 15,200 IU OD for patients above 70 kg; Fraxiparine was given 5700 IU 
twice daily (BID) for patients under 70 kg and 7600 IU BID for patients 70 kg or more. In 
Spain, patients received enoxaparin 1mg/kg BID in the first month followed by a dosage 
of 1,5mg/kg OD.
Patients with an upper extremity DVT associated with a central venous catheter (CVC) 
were ineligible because of the recommended limited anticoagulant treatment duration 
of four weeks after removal of the central venous catheter. The institutional review board 
of both the LUMC and the Ramon y Cajal Hospital IRYCIS approved the study and waived 
the need for informed consent due to the observational design.
Study endpoints and follow up procedures
The primary objective of this study was to establish the frequency of LMWH discon-
tinuation because of LMWH side effects. Reason for discontinuations were noted and 
categorized as follows: local side effects defined as hematomas at injection side, site 
pain and exanthema, and heparin induced thrombocytopenia. Secondary objectives 
were (a) to identify risk factors for LMWH discontinuation, (b) to determine the incidence 
rates of recurrent VTE, major bleeding and mortality during the follow-up period and (c) 
to identify risk factors for mortality. Predefined candidate predictors for discontinuation 
and mortality were defined as age, sex, anemia (defined as hemoglobin level less than 
7,5 mmol/L for women and less than 8,5 mmol/L for men), impaired kidney function 
(defined as a glomerular filtration rate below 60 mL/min/1.73m2 estimated with the 
Modification of Diet in Renal Disease (MDRD) equation), thrombocytopenia (defined as 
a platelet count below 150x103/L), type of cancer (solid versus hematologic), metastatic 
disease, immobilization (for at least three consecutive days) four weeks before the VTE 
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event and previous use of anticoagulation therapy. These risk factors were assessed at 
baseline in all patients.
All patients were followed were followed during LMWH treatment with a maximum of 
180 days, in which they visited the outpatient clinic on a regular basis for their oncologi-
cal treatment. Our endpoints were assessed at all these scheduled visits as well as during 
intercurrent hospitalization by standardized assessment of LWMH compliance and signs 
and symptoms of recurrent thromboembolism and bleeding episodes.
Recurrent PE was defined as a new intraluminal filling defect on pulmonary angiog-
raphy or CTPA, a new high probability perfusion defect on V/Q scan or any new defects 
after earlier normalization of the scan, or confirmation of a new PE at autopsy. V/Q-scans 
were evaluated according to the PIOPED criteria. Recurrent lower extremity DVT was 
defined as new non-compressibility by ultrasonography of the common femoral and/
or popliteal vein for lower extremity DVT in the transverse plane or the vein diameter 
under maximum compression, as measured in the abnormal venous segment, showing 
enlargement of thrombus diameter (>4mm). Major bleed was defined in accordance 
with the International Society of Thrombosis and Haemostasis criteria (16). Cause of 
death was verified by reviewing the pathology report. If autopsy was not performed, the 
likely cause of death was verified with the treating physician by reviewing the medical 
records and death certificates.
Statistical analyses
We used means (standard deviation (SD)) and medians (interquartile range (IQR)) to 
present baseline continuous baseline variables. For categorical variables, we used fre-
quencies and percentages. For analysis of primary and secondary endpoints, follow-up 
started at the moment of first LMWH administration and ended at time of LMWH discon-
tinuation, death or maximum follow-up period of 180 days. The cumulative incidences 
of LMWH discontinuation, recurrent VTE, major bleeding and death were estimated ac-
cording to the Kaplan-Meier method applying a competing risk analysis, and presented 
with two-sided 95% confidence intervals (CI) (17). We performed a backward selection 
multivariate analysis using Cox regression methods to evaluate possible predictors for 
LMWH cessation and mortality. Data were analyzed using SPSS version 22 (SPSS inc., 




During the study period, 466 patients were di-
agnosed with cancer-associated VTE, of whom 
94 were excluded for the following reasons 
– other forms of anticoagulant therapy, lost 
to follow-up and catheter-related thrombosis, 
leaving 372 patients for the current analysis 
(figure 1). Table 1 shows an overview of base-
line characteristics of the included patients. 
Their mean age was 67 years (SD 13); 204 (55%) 
were male; and half of patients had metastatic 
cancer. The majority of 339 (91%) patients had 
solid tumors, 19 (5.1%) patients had a hemato-
logic malignancy and in 14 patients the type of 
cancer was unknown.
Primary endpoint: LMWh discontinuation
A total of 194 (51%) patients discontinued LMWH treatment within six months; of whom 
78 (21%) patients stopped because of LMWH side eff ects. Unacceptable pain at the 
injection site was the most common reason of discontinuation, occurring in 33 patients 
(8.9%); 27 patients (7.3%) had large local injection site hematomas; 15 patients (4%) 
were found to have allergic reactions (local irritation or generalized exanthema) and 
three patients (0.81%) developed heparin induced thrombocytopenia. The Kaplan Meier 
survival curve for discontinuation because of side eff ects per competing risk analysis is 
shown in figure 2. LMWH treatment was stopped after a median duration of 90 days 
(interquartile range 60-120 days). The cumulative incidence (per competing risk analy-
sis) of discontinuation during six months of LMWH treatment was 21% (95%CI 17-25).
Predictors for LMWh discontinuation
Female sex was found to be signifi cantly associated with premature LMWH discontinua-
tion because of side eff ects (odds ratio (OR) 1.6; 95%CI 1.03-2.5) while both disease stage 
as well as co-morbid conditions were not (Table 2). Multivariate analysis confi rmed the 
association between female sex and LMWH discontinuation (adjusted OR 1.7; 95%CI 
1.1-2.8), and did not identify additional independent predictors.
figure 1. Flowchart of the study population.











note: DVT=Deep Vein Thrombosis
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Recurrences, bleeding and mortality
Thirty patients were diagnosed with recurrent VTE during LMWH treatment, for an 8.1% 
(95%CI 5.4-11) cumulative incidence (per competing risk analysis); of these patients 14 
suff ered a fatal VTE (47%). Major bleeding occurred in 30 patients for an 8.3% (95%CI 
5.4-11) cumulative incidence during the same follow-up period; seven major bleeding 
events were fatal (23%). Overall, 106 patients died, after a median follow-up of 48 days 
(interquartile range 6-80 days), for a cumulative incidence of 28% (95%CI 21-35). Table 3 
shows the univariate analysis of possible predictors of mortality, in which only metastatic 
cancer (OR 3.6; 95%CI 2.3-5.6) was signifi cant. After multivariate analysis, metastatic 
cancer remained a signifi cant predictor of mortality (adjusted OR 4.0; 95%CI 2.4-6.7).
Table 1. Baseline characteristics
Study patients (n=372)
Age (y), mean ± st. dev 67 ± 13
Male sex, no. (%) 204 (55)
Previous use of anticoagulation therapy, no (%) 47 (13)1
Type of malignancy, no (%) Cerebral 13 (3.5)
Non-Hodgkin lymphoma 3 (0.80)
Multiple myeloma 6 (1.6)
Other hematologic malignancy 10 (2.7)









Anaemia, no (%) 242 (65)2
Thrombocytopenia 80 (22)3
Impaired kidney function 49 (13)4
Presence of metastatic disease, no (%) 185 (50)5
Provoked VTE, no (%) 79 (21)6
Previous venous thromboembolism, no (%) 29 (7.8)
note: st. dev=Standard deviation, VTE=Venous thromboembolism
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dISCuSSIon
In this prospective observational study we found that one out of five patients with 
cancer-associated VTE discontinued LMWH injections because of side effects during a 
period of six months. The six-month cumulative incidence of discontinuation due to daily 
Table 2. Uni and multivariate analysis of predictors for LMWH discontinuation because of side effects in 
372 patients
Predictor univariate RR (95%CI) Multivariate RR (95%CI)
Age > 40 years 0.70 (0.28-1.7) 0.69 (0.25-1.9)
Female sex 1.61 (1.03-2.5) 1.7 (1.1-2.8)
Anaemia 0.89 (0.56-1.4) 1.2 (0.72-2.0)
Thrombocytopenia 1.0 (0.60-1.70) 1.1 (0.63-1.9)
Impaired kidney function 0.62 (0.29-1.4) 0.68 (0.30-1.5)
Hematologic cancer 0.41 (0.10-1.7) 1.1 (0.26-4.4)
Provoked VTE 1.0 (0.59-1.7) 0.99 (0.55-1.8)
Metastatic cancer 0.81 (0.52-1.3) 0.80 (0.49-1.3)
Previous use of anticoagulation therapy 0.89 (0.45-1.8) 0.95 (0.45-2.0)
note: RR=Relative Risk, CI=Confidence Interval, VTE=Venous Thromboembolism






























Days of follow up
LMWH discontinuation
372                       354                       348                       325                       316               307                       293      
Number of patients
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subcutaneous LMWH injections was 21%. This finding is consistent with other smaller 
and retrospective studies reporting similar percentages of patients who switched to oral 
anticoagulants within six months, although in these studies reasons for discontinuation 
were not provided (11, 13). Overall, half of the patients did not complete six months of 
LMWH treatment, which is also in line with previous studies (8-10). A remarkable finding 
was the fact that the most common reason for discontinuing LMWH treatment was pain 
at the injection site followed by injection site hematoma and allergic reactions. In this 
study, only female gender was found to be associated with discontinuation because of 
side effects.
When considering optimal management of patients with cancer-associated VTE, 
their overall prognosis and treatment preferences should be taken into account. The 
unfavorable prognosis of patients with cancer-associated VTE is clearly underlined by 
our study, reporting high cumulative incidences of mortality (28%), recurrent VTE (8.1%) 
and major bleeding (8.3%) until LMWH discontinuation, comparable with findings from 
previous landmark randomised trials after six months of follow up (4, 5). Importantly, 
although LMWH injection complications occurred in one of five patients, mirror wise 
four out five patients could continue. This may therefore be considered an acceptable 
trade-off against the reported higher risk of recurrent VTE associated with vitamin K 
antagonists (4-6). The recently introduced non-vitamin K dependent oral anticoagulants 
(DOACs) have the potential to be a valid alternative option for these patients, as these 
drugs share practical advantages with LMWH, are administered orally, and display a 
similar efficacy to VKAs but a lower bleeding risk in phase 3 studies in the general VTE 
population (18). The oral administration of DOACs might be more attractive and patient-
friendly than daily subcutaneous LMWH injections. However, the performance of these 
agents has not sufficiently been investigated in patients with cancer-associated VTE, 
and a direct comparison is lacking (19). The results of our study provide a solid basis to 
Table 3. Uni and multivariate analysis of predictors for mortality in 372 patients during LMWH treatment
Predictor univariate RR (95%CI) Multivariate RR (95%CI)
Age > 40 years 1.6 (0.52-5.2) 1.5 (0.36-6.1)
Female sex 0.85 (0.58-1.3) 0.83 (0.52-1.3)
Anaemia 1.6 (1.0-2.5) 1.4 (0.83-2.5)
Thrombocytopenia 0.64 (0.37-1.0) 0.75 (0.42-1.4)
Impaired kidney function 1.3 (0.79-2.3) 1.7 (0.96-3.2)
Hematologic cancer 0.65 (0.24-1.8) 1.2 (0.16-8.8)
Provoked VTE 0.74 (0.44-1.2) 0.65 (0.34-1.3)
Metastatic cancer 3.6 (2.3-5.6) 3.8 (2.2-6.4)
Previous use of anticoagulation therapy 1.2 (0.67-2.0) 0.94 (0.47-1.9)
note: RR=Relative Risk, CI=Confidence Interval, VTE=Venous Thromboembolism
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evaluate the use of DOACs in cancer-associated VTE. At present, the Hokusai VTE cancer 
study is randomizing patients with cancer-associated VTE to receive either dalteparin or 
edoxaban (20).
The strength of this study is the prospective multicenter set-up with a relatively 
large cohort of consecutive patients in daily practice, allowing for providing novel and 
clinically relevant data on the adherence and discontinuation due to complications of six 
months of daily subcutaneous LMWH administration in patients with cancer-associated 
VTE. We included a representative population given the fact that nearly 50% had meta-
static disease and only 4.2% was lost to follow-up. Our study had limitations as well. We 
did not collect daily compliance to the LMWH therapy, and the impact of daily LMWH 
injections on quality of life was not evaluated.
To conclude, our study reveals that one out of five patients with cancer-associated 
VTE discontinued LMWH injections within six months because of side effects. The most 
common reasons for discontinuation were pain at the injection site, injection site hema-
toma and allergic reaction. Our findings provide important background information for 
current clinical trials investigating the efficacy and safety of DOACs compared to LMWH.
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Higher adherence to treatment 
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Current guidelines recommend low-molecular-weight-heparins (LMWH) monotherapy 
for 3 to 6 months as first-line treatment for cancer-associated venous thromboembolism 
(VTE). In clinical practice enoxaparin and nadroparin are common agents used. However, 
differences in therapy adherence between these LMWHs have never been reported. 
Therefore, our aim was to compare adherence to enoxaparin and nadroparin in patients 
with cancer-associated VTE.
Materials and Methods
Consecutive patients with active cancer and objectively confirmed VTE, treated at a 
Dutch or a Spanish hospital, were followed during LMWH therapy with a maximum of 
180 days. Cumulative incidences of discontinuation of both LMWHs were estimated and 
compared according to the Kaplan-Meier method, applying a competing risk analysis to 
correct for mortality.
Results
366 patients were analysed during LMWH treatment, of whom 284 patients (78%) were 
treated with enoxaparin and 82 (22%) with nadroparin. The cumulative incidence of dis-
continuation of enoxaparin and nadroparin treatment because of side effects was 30% 
(95%CI 24-36) and 8.8% (95%CI 1.1-15) respectively. Competing risk analysis revealed a 
higher number of patients discontinuing enoxaparin due to side effects (adjusted HR: 
2.8; 95%CI 1.06-7.2). Pain at the injection site was the most common reason of discon-
tinuation in patients using enoxaparin, occurring in 32 patients, while it occurred in one 
patient using nadroparin (adjusted HR: 4.0; 95%CI 0.52-31).
Conclusion
This analysis reveals that enoxaparin was associated with a higher risk of discontinua-
tion because of side effects compared to nadroparin. However, given the nature of the 
patient groups, these findings should be followed by future studies.
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InTRoduCTIon
Low-molecular-weight heparins (LMWH) are recommended for at least three to six 
months as first-line treatment for cancer-associated venous thromboembolism (VTE) by 
most current international guidelines because of proven superior efficacy compared to 
conventional vitamin K antagonists (VKA), with comparable risk of major bleeding (1-3).
Recent research carried out at our institution has showed that one out of five patients 
with cancer-associated VTE stop LMWH injections because of side effects, mostly due 
to unacceptable pain at injection site (4). This finding was consistent with other smaller, 
retrospective studies reporting similar percentages of patients who switched to oral 
anticoagulants within six months (5, 6). These studies, however, did not distinguish 
between LMWH preparations.
In clinical practice, enoxaparin and nadroparin are commonly used LMWH agents for 
treatment of (cancer-associated) VTE. These different LMWHs are prepared by a variety 
of chemical and enzymatic depolymerisation techniques, resulting in marked differ-
ences in their physical and biochemical properties. These different characteristics might 
influence the burden of daily administration of subcutaneous injections. However, 
clinical data on the comparison of LMWHs is very limited and, so far, no single study 
has compared adherence to these LMWHs in patients with cancer-associated VTE. Two 
preliminary studies including heterogeneous patients have compared local tolerance of 
enoxaparin and nadroparin and suggested that the latter was locally better tolerated, 
possibly due to the difference in cationic salt composition (7, 8). Thus, more accurate 
detailed information about adherence to different LMWHs for the treatment of cancer-
associated VTE is required.
The aim of the current study was to compare adherence to daily subcutaneous injec-
tions of enoxaparin and nadroparin in patients with cancer-associated VTE.
MaTeRIaLS and MeThodS
Study population
This was a prospective, multi-centre, cohort follow-up study of consecutive patients 
with active cancer and objectively confirmed symptomatic proximal deep venous 
thrombosis (DVT) and/or pulmonary embolism (PE) to compare the adherence to 
enoxaparin and nadroparin during treatment with a maximum of 180 days. The design 
and characteristics of this cohort study have been described previously(4). However, in 
this study, only patients from the Leiden University Medical Centre (the Netherlands) 
and the Ramon Y Cajal hospital IRYCIS (Spain) with cancer-associated VTE between 2004 
and 2014 and treated with therapeutic doses of LMWH were eligible for inclusion. In 
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these hospitals, two specific LMWH preparations were used; in Spain, all patients were 
treated with enoxaparin (enoxaparinum sodium 100mg (10,000 U/ml)) between 2004 
and 2012 in the recommended dose of 1 mg/kg body weight twice daily (BID) in the 
first month, followed by as dosage of 1,5 mg/kg once daily (OD). In the Netherlands, all 
patients received weight-adjusted doses of subcutaneous nadroparin (nadroparinum 
calcium 9500 U/ml) between 2010 and 2014, either given once or twice daily - Fraxodi 
was given by 11,400 IU OD for patients under 70 kg and 15,200 IU OD for patients above 
70 kg; Fraxiparine was given 5700 IU BID for patients under 70 kg and 7600 IU BID for 
patients 70 kg or more. At both hospitals, outpatient care comprised self-injections 
after standardized instructions by a trained nurse. All patients were followed during 
LMWH treatment with a maximum of 180 days and were excluded if they received other 
anticoagulants, were lost to follow up or experienced a venous catheter-associated 
thrombosis.
The institutional review board of both the Leiden University Medical Centre and the 
Ramon y Cajal Hospital IRYCIS approved the study and waived the need for informed 
consent due to its observational design.
Study endpoints
The primary objective of this study was to compare the discontinuation rate because of 
side effects of enoxaparin and nadroparin during the six-month study period. Reasons 
for discontinuation were determined by the treating physician during hospital visitation 
and categorized as follows: local side effects defined as hematomas at injection side, site 
pain and exanthema, and heparin induced thrombocytopenia. Patients were classified 
as having heparin-induced thrombocytopenia after a presumptive diagnosis, based on 
clinical parameters such as timing and degree of platelet count drop. The secondary 
objectives were to compare the incidences of recurrent VTE, major bleeding and mortal-
ity of both LMWHs.
Recurrent lower extremity DVT was defined as new non-compressibility by ultraso-
nography of the common femoral and/or popliteal vein for lower extremity DVT in the 
transverse plane or the vein diameter under maximum compression, as measured in 
the abnormal venous segment, showing enlargement of thrombus diameter (>4mm). 
Recurrent PE was defined as a new intraluminal filling defect on pulmonary angiography 
or CTPA, a new high probability perfusion defect on V/Q scan or any new defects after 
earlier normalization of the scan, or confirmation of a new PE at autopsy. V/Q-scans were 
evaluated according to the PIOPED criteria. Major bleed was defined in accordance with 
the International Society of Thrombosis and Haemostasis criteria(9). Cause of death was 
verified by reviewing the pathology report. If autopsy was not performed, the likely 
cause of death was verified with the treating physician by reviewing the medical records 
and death certificates. All secondary outcomes were adjudicated within the study group.
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Statistical analyses
Means (standard deviation (SD)) and medians (interquartile range (IQR)) were used to 
present baseline continuous baseline variables for both LMWH groups. For categorical
Means (standard deviation (SD)) and medians (interquartile range (IQR)) were used to 
present baseline continuous baseline variables for both LMWH groups. For categorical 
variables, we used frequencies and percentages. The Pearson’s Chi-square test was used 
to compare the distribution of the categorical variables, whereas the Mann-Whitney and 
independent t-test were used for non-normal and normal distributed continuous vari-
ables respectively. For analysis of primary and secondary endpoints, follow-up started at 
the moment of first LMWH administration and ended at time of LMWH discontinuation 
or the maximum follow-up period of 180 days. The cumulative incidence of discontinu-
ation of both LMWHs, recurrence VTE and bleeding events were estimated according to 
the Kaplan-Meier method, presented with two-sided 95% confidence intervals (CI). A 
comparison was then made by a Cox-proportional hazard model, adjusted for gender, 
age, impaired kidney function and metastatic cancer, applying a competing risk analysis 
in which a patient was either censored for a specified outcome or not, and in the latter 
case completed the entire follow up period (demonstrated with a Hazard Ratio (HR))(10). 




A total of 366 patients were analysed during LMWH treatment, of whom 284 patients 
(78%) were treated with enoxaparin and 82 (22%) with nadroparin (67 patients (82%) 
with Fraxodi OD and 15 (18%) with Fraxiparin BID). Table 1 shows the baseline char-
acteristics of both LMWH therapies. Patients receiving enoxaparin were significantly 
older (mean age 68 years (SD 12) vs. 62 years (SD 13)). Impaired kidney function and 
metastatic cancer were more present in patients treated with nadroparin (27% vs. 9.7% 
and 63% vs. 45% respectively).
discontinuation of LMWh treatment
Overall, 192 patients (52%) discontinued LMWH treatment within six months, of whom 
151 patients (53%) were treated with enoxaparin and 41 patients (50%) with nadroparin. 
Reasons for discontinuation are shown in Table 2. A total of 77 patients (21%) discon-
tinued LMWH treatment because of side effects; of whom 71 patients (92%) stopped 
enoxaparin after a median duration of 90 days (IQR 30-90 days) and six patients (7.8%) 
nadroparin after a median duration of 66 days (IQR 19-125 days; five patients using 
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Table 2. Reasons for LMWH discontinuation
Reason, no (%) nadroparin (n=82) enoxaparin (n=284)
Recurrent VTE 1 (1.2) 18 (6.3)
Bleeding 3 (3.6) 8 (2.9)
Death* 27 (33) 52 (18)
Curation of cancer 1 (1.2) 2 (0.7)
LMWH side effects 6 (7.3) 71 (25)
Other 2 (2.4) 0
Unknown 1 (1.2) 0
Total 41 (50) 151 (53)
note: VTE=Venous Thromboembolism
Table 1. Baseline characteristics
nadroparin (n=82) enoxaparin (n=284)
Age (y), mean ± st. dev 62 ± 12 68 ± 13*
Male sex, no. (%) 51 (62) 152 (54)
Previous use of anticoagulation therapy, no (%) 16 (20) 31 (11)*
Type of malignancy, no (%) Cerebral 3 (3.7) 10 (3.5)
Non-Hodgkin lymphoma 2 (2.4) 1 (0.40)
Multiple myeloma 4 (4.9) 2 (0.70)*
Other haematologic 
malignancy
6 (7.3) 4 (1.4)*
Women genital tract 15 (18) 19 (6.7)*
Breast 4 (4.9) 49 (17)*
Testis 1 (1.2) 1 (0.40)
Stomach 2 (2.4) 10 (3.5)
Colon 3 (3.7) 29 (10)
Other gastrointestinal 12 (15) 14 (4.9)*
Lung 14 (17) 46 (16)
Other 16 (20) 85 (30)
Unknown 0 14 (15)*
Anaemia, no (%) 53 (65) 188 (66)
Thrombocytopenia, no (%) 17 (21) 63 (22)
Impaired kidney function, no (%) 22 (27) 27 (9.7)*
Presence of metastatic disease, no (%) 52 (63) 127 (45)*
Immobilisation in the past four weeks, no (%) 21 (26) 28 (9.9) *
Previous venous thromboembolism, no (%) 7 (8.5) 21 (7.4)
note: st. dev=Standard deviation
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fraxodi OD, one patient using fraxiparin BID). The Kaplan Meier survival for discontinua-
tion of both LMWHs because of side effects is shown in figure 1. The overall cumulative 
incidence of discontinuation during six months of enoxaparin and nadroparin treatment 
was 30% (95%CI 24-36) and 8.8% (95%CI 1.1-15) respectively. Competing risk analysis 
revealed a significant higher number of patients discontinuing enoxaparin (adjusted HR: 
2.8; 95%CI 1.06-7.2).
Table 3 shows LMWH side effects that led to discontinuation. Interestingly, pain at the 
injection site was the most common reason of discontinuation in patients using enoxapa-
rin, occurring in 32 patients (cumulative incidence: 15% (95%CI 10-19)), while it occurred 
in one patient using nadroparin (cumulative incidence: 1.7% (95%CI 0-5.0);adjusted HR: 
4.0; 95%CI 0.52-31). Discontinuation because of local exanthema only occurred in 15 
patients who were treated with enoxaparin (cumulative incidence: 7.1% (95%CI 3.6-11).
Recurrent VTe, bleeding and mortality
During the six month study period, a recurrent VTE occurred in 23 patients treated with 
enoxaparin after a median duration of 60 days (IQR 27-120 days) and in six patients 
treated with nadroparin after a median duration of 118 days (IQR 34-180 days), for a re-
spective cumulative incidence of 11% (95%CI 6.4-15) and 7.6% (95%CI 1.8-13; adjusted 
HR: 2.9; 95%CI 0.65-13). Major bleeding events occurred in 27 patients using enoxaparin 



























Days of follow up
Discontinuation  both LMWHs 
because of side effects
Enoxaparin
Nadroparin
Table 3. Reasons for LMWH discontinuation because of side effects
Reason, no (%) nadroparin (n=82) enoxaparin (n=284)
Heparin induced thrombocytopenia 2 (2.4) 1 (0.035)
Hematoma at injection site 3 (3.7) 23 (8.1)
Local exanthema 0 15 (5.3)
Pain 1 (1.2) 32 (11)
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after a median duration of 90 days (IQR 30-120 days) and in two patients using nad-
roparin after a median duration of 66 days (IQR 34-66 days), for a respective 11% (95%CI 
6.9-15) and 2.7% (95%CI 0-6.4) cumulative incidence (adjusted HR: 5.1; 95%CI 0.66-39).
Seventy-one patients died during enoxaparin treatment after a median duration of 60 
days (IQR 30-90 days) and 30 patients died during nadroparin treatment after a median 
duration of 77 days (IQR 30-140), for a respective cumulative incidence of 29% (95%CI 
23-34) and 39% (95%CI 29-49; adjusted HR: 1.3; 95%CI 0.76-2.3).
dISCuSSIon
Our main observation was a significantly higher risk of discontinuation of LMWH 
treatment because of side effects of enoxaparin than of nadroparin in patients with 
cancer-associated VTE. During the six-month study period, the adjusted hazard ratio of 
discontinuation because of side effects of enoxaparin was 2.8 compared to nadroparin 
treatment. These results elaborate on the findings of our previous study demonstrating 
a cumulative incidence of one out of five patients discontinuing both LMWHs due to 
side effects (4). The observed 30% cumulative incidence of discontinuation of enoxapa-
rin was substantially higher than described in a previous study, reporting an incidence 
of 14% in a very small number of younger cancer patients treated with a similar dose 
(11). In comparison, the observed 8.8% cumulative incidence of discontinuation of 
nadroparin was consistent with those of a previous report, studying only patients with 
metastatic or locally advanced solid cancer (12).
Pain at the injection site was the most common reason of discontinuation in patients 
using enoxaparin (45%), while occurring in only one patient using nadroparin (14%). 
This finding is in line with previous studies reporting a higher incidence of pain at the 
injection site in patients using enoxaparin than in patients using nadroparin, although 
these studies deal with different patient groups and a relatively short study period (7, 
8). They suggested that the pain intensity increased with the sodium concentration in 
enoxaparin, while in contrast, nadroparin is salified with calcium. Regarding pharmaco-
dynamics and kinetics, only slight differences exist between both LMWHs (13-15). Thus, 
the sodium concentration in enoxaparin might be responsible for increased pain at the 
injection site, thereby leading to early discontinuation. However, since the proportion of 
salt dissolved in the LMWH preparations is almost negligible and other licensed LMWHs 
for the treatment of cancer-associated VTE (i.e. tinzaparin and dalteparin) also contain 
sodium, this hypothesis seems unlikely. Unfortunately, no data were available on needle 
size differences of both LMWHs, which could also have contributed to our findings. A 
former study, however, found no reduction of pain and hematoma size in patients with 
cardiovascular disease using enoxaparin with two different needle gauges (16). Discon-
Adherence to nadroparin and enoxaparin for cancer related VTE 57
tinuation because of local exanthema only occurred in 15 patients using enoxaparin 
(cumulative incidence: 7.1%). This finding differs from a previous prospective study 
demonstrating a higher incidence proportion of heparin-induced skin lesions in patients 
treated with nadroparin (17%) than enoxaparin (3.9%) in 321 patients who used LMWH 
for a minimum of seven days (17). However, from all these reports, it is unclear whether 
the occurrence of side effects was a reason for discontinuation of therapy.
Comparative studies have not been performed to determine whether one LMWH is 
superior over the other in the treatment of cancer-associated VTE. In this study we found 
similar incidences of recurrent VTE and bleeding events of both LMWH agents.
This study has strengths and limitations. We included a large cohort providing novel 
and clinically relevant data on adherence to two different commonly used LMWH thera-
pies in cancer-associated VTE. The most important limitation of this study was the non-
randomised design. Both LMWHs were allocated according to the policy of the treating 
hospital and availability in the regional Dutch and Spanish pharmacies, thereby leading 
to differences in patient characteristics. Moreover, the evaluation of primary outcomes 
were not standardized, as treating physicians were only requested to report the reason 
of discontinuation and a HIT diagnosis was based on clinical assumption. For practical 
reasons, we combined two prospective databases (e.g. Spanish and Dutch cohorts) with 
a different time frame of inclusion. We do not believe this would have influenced the dis-
continuation rate. During the ten-year inclusion period of enoxaparin, possible changes 
in composition or preparation techniques did not lead to different discontinuation rates. 
However, because of different inclusion durations, patients were not equally distributed 
among both groups. Additionally, in our adjusted analyses, it was not possible to correct 
for all potential confounders. Other characteristics such as social economic status and 
health coverage might also have influenced these findings. Furthermore, all Spanish pa-
tients were treated with enoxaparin injections BID for the first month, which could have 
led to a higher discontinuation rate. However, discontinuation of enoxaparin occurred 
only in 25% of the patients during the first month of BID administration. In comparison, 
of the 18% BID using nadroparin patients, only one discontinued during the six month 
treatment period. Hence, this was presumably of minor influence. Lastly, given the oc-
currence of relatively small number of individual reasons for discontinuation, our study 
did not achieve adequate power to detect possible significant differences between side 
effects of these two LMWHs.
In conclusion, our study reveals a significantly higher risk of discontinuation because 
of side effects of enoxaparin than nadroparin treatment in patients with cancer-associ-
ated VTE. However, these findings should be interpreted with caution owing to inherent 
patient groups, and more studies are needed to corroborate our findings.
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After elective aortic valve replacement patients are at risk of developing valve thrombo-
sis and systemic arterial thromboembolism. Current guidelines recommend antithrom-
botic therapy with aspirin or vitamin K antagonists (VKA) during the first three months 
after the procedure but have level 2 or 3 evidence. As a consequence, the most appropri-
ate antithrombotic therapy is still a matter of debate. This retrospective study analysed 
all thromboembolic and bleeding complications in patients with either antiplatelet or 
anticoagulation therapy one year after bioprosthetic aortic valve replacement.
Methods
A total of 402 patients undergoing bioprosthetic aortic valve implantation at the VU 
University Medical Centre (VUmc) and subsequently treated at three regional hospitals 
were included. The individual duration of either vitamin K antagonists (acenocoumarol) 
or aspirin was determined and related to thrombotic and bleeding events. Patients 
were followed and censored at 1 year postoperatively for survival, cerebral ischemia, 
myocardial infarction, peripheral arterial embolism and minor and major haemorrhages.
Results
A total of 24 thromboembolic complications and 31 bleeding episodes occurred. Multi-
variable analyses revealed that acenocoumarol caused more bleedings (relative risk (RR): 
8.41, 95%CI: 3,58-19.79) and a similar amount of thromboembolic events (RR: 1.2, 95% 
CI: 0.47-3.02) compared to aspirin. Prior use of acenocoumarol was found to be a risk 
factor for thromboembolic events (RR: 3.1, 95% CI: 1.31 to 7.19). Gender, dyslipidemia, 
prior percutaneous coronary intervention, prior use of acenocoumarol and concomitant 
coronary artery bypass grafting were found to be predictors for bleeding events.
Conclusions
In patients one year following bioprosthetic aortic valve replacement, acenocoumarol 
therapy was associated with a significant increased risk in bleeding events and no reduc-
tion of thromboembolic events compared to antiplatelet therapy. These findings sup-
port the recommendations of aspirin over VKA as post-operative thromboprophylaxis 
one year postoperatively.
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InTRoduCTIon
Patients undergoing artificial heart valve replacement are at risk of developing valve 
thrombosis and systemic thromboembolism. The annual risk of thromboembolic events 
in patients with a mechanical aortic valve is 1-2% versus 0.7% with a bioprosthetic aortic 
valve, even with appropriate antithrombotic therapy (1). The need for lifelong anticoag-
ulant therapy is well established in all patients with mechanical heart valves. In patients 
with bioprosthetic aortic valves anticoagulant therapy is warranted in the presence of 
thromboembolic risk factors including atrial fibrillation, previous thromboembolism, 
left ventricular dysfunction and hypercoagulable condition. In patients without one 
of these risk factors, the appropriate antithrombotic regimen postoperatively is still a 
matter of debate.
Recommendations of current guidelines are shown in Table 1 (1-4). Although based 
on small or retrospective studies without conclusive results, there is a trend towards the 
recommendation of aspirin after implantation of a bioprosthetic aortic valve (2, 5-10). 
Therefore, after the 1st of July 2011, the antithrombotic policy in the VU University medi-
cal centre (VUmc) was changed and patients with sinus rhythm did no longer receive 
VKA.
Earlier studies demonstrated that, despite guidelines published by several profes-
sional societies, medical practice for the prevention of thrombotic events early after 
bioprosthetic aortic valve replacement varies widely among cardiac surgical centres 
(11-14). Thus, despite recommendations, there is still disparity of opinions in clinical 
practice.
Table 1. Current recommendations for antithrombotic strategy after bioprosthetic aortic valve replace-
ment in patients who are in regular sinus rhythm and have other indications for VKA therapy (1-4).
Organization, year Recommendation Grade of evidence
ESC, 2012 Low-dose aspirin should be considered for the first three months after 
implantation of an aortic bioprosthesis
2C
ACC/AHA,2014 Aspirin 75 mg to 100 mg per day is reasonable in all patients with a 
bioprosthetic aortic valve. Anticoagulation, with a VKA, to achieve 
an INR of 2.5 may also be reasonable for the first 3 months after 
bioprosthetic AVR
2B
ACCP, 2012 In patients with aortic bioprosthetic valves we suggest aspirin (50-100 
mg/d) over VKA therapy in the first 3 months
2C
EACTS, 2008 After tissue aortic valve replacement anticoagulation therapy is 
reasonably safe and may be beneficial. Antiplatelet therapy alone 
however is an acceptable alternative
2B
note: ESC = European Society of Cardiology, ACC= American College of Cardiology, AHA= American Heart 
Association, ACCP= American College of Chest Physicians, EACTS= European Association for Cardio-Thorac-
ic Surgery, VKA= Vitamin K Antagonists.
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In summary, antithrombotic management after bioprosthetic aortic valve replace-
ment is still a matter of debate. Therefore, the purpose of this study was to analyse 
thromboembolic events and bleeding complications in patients with either antiplatelet 
or anticoagulation therapy one year following bioprosthetic aortic valve surgery. For 
this purpose, different antithrombotic regimens before and after 2011 were compared. 
In addition, individual duration of either vitamin K antagonists or aspirin was related to 
thrombotic and bleeding events.
MaTeRIaLS and MeThodS
The local Human Subjects Committee of the VU University Medical Centre approved this 
retrospective evaluation and waived the requirement to obtain informed consent.
This was an observational retrospective study of consecutive patients who underwent 
an isolated bioprosthetic aortic valve replacement to measure postoperative outcomes. 
Data were collected from the prospective database of the department of cardiothoracic 
surgery of the VUmc. Patients had undergone isolated aortic valve replacement between 
2008 and 2014 and had been subsequently seen in three regional hospitals. In all three 
hospitals postoperative medical files were obtained and evaluated. Additionally, the 
thrombosis service was consulted about the duration of the treatment, the international 
normalized ratios (INRs), and target values of patients who received the vitamin K antag-
onist drug acenocoumarol. Except for patients undergoing concomitant bypass surgery, 
all other patients with concomitant procedures were excluded. Thromboembolic events 
and bleeding complications that occurred at the first postoperative day were not taken 
into consideration because antithrombotic treatment was started only at this day.
All patients were operated at the department of cardiac surgery at the VUmc and 
received an aortic bovine pericardial bioprosthesis (type, Carpentier-Edwards PERI-
MOUNT, Edwards Lifesciences, USA). Low-molecular-weight heparin (LMWH) nadroparin 
2850 IU/day, or 2850 IU twice a day if a patient’s weight was above 100 kg, was started 
on the first postoperative day followed by acenocoumarol or aspirin. Nadroparin was 
continued until acenocoumarol reached therapeutic levels, as shown by a prothrombin 
time (PT) according to the international normalized ratio (INR) (range, 2.5 to 3.5 accord-
ing to the Dutch Thrombosis Service guidelines) or as soon as the patient was ambulant 
when patients received aspirin. Anticoagulation with acenocoumarol was maintained 
for three postoperative months, then discontinued at the discretion of the referring car-
diologist and most often replaced by aspirin. Those with concomitant coronary artery 
bypass grafting did not receive double antithrombotic therapy (warfarin plus aspirin) 
but received aspirin only. After 1st of July 2011, a new treatment regimen was installed in 
the VUmc and patients no longer received standard VKA treatment bridged by LMWH. 
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The policy was changed because of lack of scientific evidence for indication of VKA and 
also anecdotal reporting of post-operative complications due to VKA therapy, especially 
early tamponade (2). From then on, aspirin (100mg per day) was started on the first 
postoperative day and continued lifelong in patients with sinus rhythm (see table 2 
regimes). Aspirin therapy could be changed to VKA therapy if thrombotic risk factors 
such as atrial fibrillation and thromboembolism were present.
To establish the exact period of the administration of acenocoumarol within a year, 
the thrombosis service was consulted. The exact period of aspirin use was assumed to 
be according to the prescription of the treating physician without interruption. Patients 
were followed and censored at one-year for administrative reasons and were observed 
on occurence of death, cerebral ischemia, including cerebrovascular accidents (CVAs) 
and transient ischemic attacks (TIAs), peripheral embolisms, myocardial infarction and 
minor and major bleeding. All thromboembolic events were defined according to the 
guideline reported by Edmunds et al. (15). Bleeding was defined as major if overt and 
associated with a decrease in hemoglobin level of 2 g per decilitre or more, required the 
transfusion of 2 or more units of blood, occurred into a critical site – i.e. intracerebral, 
intra-ocular, intraspinal, or intra-articular, or contributed to death. Clinically relevant 
non-major bleeding was defined as overt bleeding not meeting the criteria for major 
bleeding but associated with medical intervention, contact with a physician, interrup-
tion of antithrombotic treatment, or discomfort or impairment in carrying out activities 
of daily life. These events were examined in relation to the antithrombotic therapy and in 
relation to potential predictive risk factors such as gender, age, diabetes, hypertension, 
dyslipidemia, a history of smoking, prior embolism, prior cardiac surgery and prior use 
of antithrombotic therapy. Risk factors were defined according to the documentation 
provided by the treating physician.
Table 2. Post-operative antithrombotic strategies of different regional hospitals after bioprosthetic aortic 
valve replacement, in the absence of risk factors. Change of policy was at the 1st of July 2011
antithrombotic Strategy
Regional hospital before change of policy after change of policy
MCA three months acenocoumarol substituted with life-long aspirin life-long aspirin
ZMC three months acenocoumarol substituted with life-long aspirin if 
concomitant coronary artery disease
life-long aspirin
KG three months acenocoumarol substituted with life-long aspirin life-long aspirin
note: MCA = Medical Centre of Alkmaar, ZMC = Zaans Medical Centre, KG = Kennemer Gasthuis
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Statistics
Baseline characteristics were stratified according to patients who underwent surgery 
before and after policy change of the VUmc in 2011. The Pearson’s Chi-square test was 
used to compare the distribution of categorical variables, whereas the Mann-Whitney 
and independent t-tests were used for non-normal and normal distributed continuous 
variables respectively. Purely for descriptive purposes for thromboembolic and bleeding 
events we calculated Kaplan-Meier curves over a year. Patients were censored at date of 
last medical chart documentation or after loss to follow-up.
Risk (Rate) Ratios (RRs) for the occurrence of thromboembolic and bleeding events 
on the cumulative number of days of antithrombotic therapy of one antithrombotic 
therapy versus the other were estimated with Poisson regression using generalized 
estimating equations (GEE). To assess the influence of independent predictive risk fac-
tors on thromboembolic and bleeding events a multivariable Poisson regression was 
performed using all potential risk factors simultaneously which in univariable Poisson 
regressions had a p-value lower than 0.15 and those of clinical importance. All analyses 
were performed using SPSS version 21.
ReSuLTS
In total 402 patients were included (mean age 75 years, 56.2% men). Table 3 shows an 
overview of baseline characteristics. The individual duration of either acenocoumarol 
or aspirin use could be assessed in 384 patients and related to the number of throm-
boembolic and bleeding events. In 22 patients data on the exact number of days of 
medication use were not complete, because detailed information of potential therapy 
changes could not be retrieved from medical files. As expected, the cumulative number 
of days of aspirin use was less before than after the adjustment of treatment policy. 
A total of 51 patients experienced an event; 20 patients had a thromboembolic event 
and 26 patients had a bleeding episode. In four patients both a thromboembolic and 
a bleeding event occurred. One patient had two minor bleeding events. The number 
of events before and after 2011 did not differ significantly (bleeding events: p= 0.35, 
thromboembolic events: p=0.59).
Table 4 lists the sites of bleeding and thromboembolic events and the treatment regi-
men. Of 31 bleeding events, 14 were major bleedings. Most bleedings were gastrointes-
tinal (42%) of which one was fatal. In total, 81% of the bleeding events occurred during 
treatment with acenocoumarol. Most of the thromboembolic events were transient 
ischemic attacks (41%). The patient who experienced a myocardial infarction received 
both aspirin and acenocoumarol. The occurrence of thromboembolic events was similar 
for both acenocoumarol and aspirin.
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Table 3. Baseline characteristics
Characteristic




Age (y), mean ± st. dev 74,9 ± 6,9 76,0 ± 6,6 74,2 ± 7,1
Gender male 226 (56,2) 86 (52,8) 140 (58,6)
female 176 (43,7) 77 (47,2) 99 (41,4)
logEuroscore, mean ± st. dev 7,3 ± 5,1 8,3 ± 5,7 6,5 ± 4,5*
missing, no. 19 19
Prior CVA, , no (%) 29 (7,2) 11 (6,7) 18 (7,5)
Prior MI, no (%) 37 (9,2) 9 (5,5) 28 (11,7)*
Prior embolism, no (%) 42 (10,4) 19 (11,7) 23 (9,6)
LV function, no (%) >40% 355 (88,3) 146 (89,6) 209 (87,4)
20-40% 32 (8,0) 12 (7,4) 20 (8,4)
<20% 14 (3,5) 5 (3,1) 9 (3,8)
missing 1 (0,2) 0 1 (0,4)
Preoperative AF, no. (%) 51 (12,7) 22 (13,5) 29 (12,1)
missing 31 (7,7) 7 (4,3) 24 (10)
Dyslipidemia, no. (%) 130 (32,3) 48 (29,4) 82 (34,3)
missing 1 (0,2) 1 (0,6)
Previous CABG, no. (%) 14 (3,5) 5 (3,1) 9 (3,8)
Previous PCI, no. (%) 44 (10,9) 13 (8,0) 31 (13,0)
Smoking, no. (%) 75 (18,7) 30 (18,4) 45 (18,8)
Preoperative aspirin, no. (%) 178 (44,3) 81 (49,7) 96 (40,2)
Previous acenocoumarol, no. (%) 59 (14,7) 17 (10,4) 43 (18,0)*
Aortic disease, no. (%) stenosis 353 (87,7) 143 (87,7) 210 (87,9)
regurgitation 21 (5,2) 8 (4,9) 13 (5,4)
mixed 27 (7,6) 11 (6,7) 16 (6,7)
missing 1 (0,2) 1 (0,6) 0
Concomitant CABG, no. (%) 169 (42) 73 (44,8) 96 (40,2)
missing, no. 2 2 0
Repeat thoracotomy, no (%) 25 (6,2) 17 (10,4) 8 (3,3)*
missing 31 (7,7) 0 31 (13,0)
Sum of days of therapy use, days (median) Aspirin 67725 (202) 22028 (162) 46062 (242)*
Acenocoumarol 56469 (112,5) 30482 (154) 25987 (0)*
missing, no. 18 12 6
Number of bleeding events, no. (%) 32 (8,0) 16 (9,8) 16 (6,7)
Number of thromboembolic events, no. (%) 24 (6,0) 11 (6,7) 13 (5,4)
note: y=years, st. dev.=Standard Deviation, CVA=Cerebrovascular Accident, MI=Myocardial Infarction, 
LV=Left-ventricular, AF=Atrial Fibrillation, CABG=Coronary Artery Bypass Graft, PCI=Percutaneous Coro-
nary Intervention
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Univariable analysis of risk factors on events is shown in Table 5. There was a highly 
increased risk in the incidence of bleeding events when using acenocoumarol after one 
year of follow-up compared to aspirin (RR: 18.32, 95% CI: 5,41 to 62,07). In addition, seven 
other risk factors were predictive for bleedings: gender (p=0.001), age (p<0.001), prior 
percutaneous coronary intervention (p<0.001), hypertension (p=0.004), dyslipidemia 
(p<0.001) and concomitant coronary artery bypass grafting (p<0.001). In multivariable 
analysis the incidence of bleeding events remained significantly higher in patients using 
acenocoumarol compared to patients with aspirin use (RR: 8.41, 95%CI: 3.58 to 19.79). 
Gender, prior percutaneous coronary intervention, dyslipidemia, prior use of acenocou-
marol and concomitant coronary artery bypass grafting remained all independent pre-
dictors for bleeding events (Table 6). Also for major bleedings acenocoumarol remained 
a predictor in univariable and multivariable analyses (multivariable: RR: 14.60, 95%CI: 
1.95 to 109.37). For thromboembolic events, both in uni- and multivariable analysis, 
there was no significant difference one year postoperatively when using acenocoumarol 
or aspirin (multivariable RR: 1.2, 95% CI: 0.47-3.02). Only prior use of acenocoumarol 
appeared to be an independent predictor of thromboembolic events both in uni- and 
multivariable analysis (p=0.007).
Kaplan Meier survival curves for the first episode of any event, including mortality, 
are shown in figure 1. 50% of the bleeding and 63% of the thromboembolic complica-
tions occurred within 3 months. Comparing the events before and after policy change in 
Table 4. Bleeding and thromboembolic events
Antithrombotic therapy
No. Events Acenocoumarol Aspirin Neither
Bleeding events   32 26 (81%) 6 (19%) 0
Site of events, no. (%)
Cerebral 2 (6%) 2 (100%) 0 0
Gastrointestinal 14 (44%) 11 (79%) 3 (21%) 0
Urinary 7 (22%) 5 (83%) 1 (17%) 0
Epistaxis 4 (13%) 3 (75%) 1 (25%) 0
Other 5 (16%) 4 (80%) 1 (20%) 0
TE events 24* 12 (52%) 11 (45%) 2 (8%)
Site of events, no. (%)
CVA 7 (32%) 3 (43%) 4 (57%) 0
TIA 9 (41%) 6 (67%) 2 (22%) 1 (11%)
Myocardial infarction 1 (4,5%) 1 (50%) 1 (50%) 0
Pulmonary embolism 1 (4,5%) 0 1 (100%) 0
Deep vein thrombosis 2 (9%) 0 1 (50%) 1 (50%)
other 4 (18%) 2 (50%) 2 (50%) 0
note: CVA = Cerebrovascular Accident, TIA = Transient Ischemic Attack
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Table 5. Univariable analysis of risk factors on bleeding and thromboembolic events in 384 patients (unless 
specified otherwise) one year after bioprosthetic aortic valve replacement.
Variable
Bleeding events TE events
RR 95%CL P-value RR 95%CL P-value
Acenocoumarol 18,32 5,41-62,07 <0,001 1,11 0,44-2,77 0,83
Male 0,15 0,05-0,46 0,001 0,815 0,36-1,85 0,62
Age 1,07 1,04-1,11 <0,001 1,01 0,95-1,07 0,8
LogEuroscore (n=365) 1,04 0,98-1,12 0,21 0,99 0,93-1,07 0,97
Prior CVA 2,01 0,64-6,36 0,23 1,2 0,30-4,92 0,79
Prior CABG 0,24 0,03-2,17 0,2 1,37 0,20-9,39 1,75
Prior PCI 32,09 17,26-59,66 <0,001 0,8 0,20-3,31 0,76
Prior embolism 0,31 0,06-1,58 0,16 0,87 0,21-3,56 0,84
Diabetes 1,5 0,74-3,04 0,26 1,43 0,58-3,54 0,44
Smoking 0,34 0,08-1,36 0,13 1,34 0,51-3,52 0,55
Hypertension 6,2 1,82-21,3 0,004 1,47 0,60-3,59 0,4
Dyslipidemia (n=383) 4,74 3,00-7,48 <0,001 1,27 0,54-2,96 0,58
Repeat thoracotomy (n=354) 0,54 0,08-3,75 0,53 0,85 0,12-5,60 0,87
Prior ASA (n=381) 1,47 0,77-2,78 0,24 0,72 0,30-1,70 0,45
Prior Acenocoumarol (n=381) 0,27 0,5-1,35 0,11 3,06 1,31-7,19 0,01
History of AF (n=351) 0,65 0,20-2,07 0,46 1,55 0,52-4,57 0,43
Concomitant CABG 2,83 2,13-3,76 <0,001 1,55 0,68-3,52 0,3
Before policy change 0,54 0,21-1,39 0,21 0,79 0,26-2,39 0,67
note: TE = thromboembolic, RR=Relative Risk, CI=Confidence Interval, MI= Myocardial infarction, CVA = 
Cerebrovascular Accident, CABG= Coronary Artery Bypass Grafting, PCI=Percutaneous Coronary Interven-
tion, AF= Atrial Fibrillation
Table 6. Multivariable Poisson regression with selected independent predictors that had p-values below 




RR 95%CI P-value  RR 95%CI P-value
Acenocoumarol 8,41 0,36-19,79 <0,001 1,2 0,47-3,02 0,7
Male 0,14 0,36-1,62 <0,001 0,82 0,36-1,89 0,65
Age 1,02 0,96-1,08 0,49 1,01 0,95-1,07 0,77
Prior MI 0,35 0,07-1,69 0,19 - - -
Prior PCI 10,75 5,54-20,88 <0,001
Smoking 1,6 0,65-3,95 0,31 - - -
Hypertension 1,82 0,80-4,16 0,16 - - -
Dyslipidemia (n=383) 2,29 1,26-4,19 0,007 - - -
Prior Acenocoumarol (n=381) 2,46 1,32-4,56 0,004 3,1 1,37-7,4 0,007
Concomitant CABG 3,32 1,70-6,48 <0,001 - - -
note: TE = thromboembolic, RR=Relative Risk, CI=Confidence Interval, MI = myocardial infarction, PCI = 
percutaneous coronary intervention, CABG = coronary artery bypass surgery.
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figure 1. Survival to bleeding ( A ), thromboembolic events ( B ) and overall survival ( C ) in 402 patients 1 




Blue = before policy change 2011, green = after policy change 2011.
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2011, no signifi cant diff erence in event-free survival could be demonstrated (bleeding: 
p=0.48, thromboembolism: p=0.83, mortality: p=0.58), possibly due to the larger num-
ber of patients using acenocoumarol preoperatively, which is a predictor for bleeding, 
after policy change in 2011. During one year follow-up 10 patients (2%) died, of who 
four died before the antithrombotic policy change at the VUmc. Approximately 50% 
of all events occurred within 100 days after aortic valve implantation. Causes of death 
were sepsis (three patients), cardiac arrest, gastrointestinal bleeding, aortic dissection, 
respiratory failure and post-anoxic encephalopathy. In one patient, the cause of death 
was unknown.
dISCuSSIon
The main fi nding of this study was a signifi cantly increased incidence of minor and major 
bleeding events without a reduction of thromboembolic events during acenocoumarol 
therapy compared to aspirin use one year after bioprosthetic aortic valve replacement.
Our study reinforces the recommendations of the ACC/AHA, ACCP, ESC and the EACTS 
guidelines suggesting antiplatelet therapy as adequate or acceptable thromboprophy-
laxis. These recommendations have been revisited in the last decade after more recent 
publications about the absence of a benefi cial eff ect of warfarin (1-4). Five studies have 
compared antiplatelet with anticoagulation therapy in patients with bioprosthetic aor-
tic valves (Table 7) (5-7, 16, 17). Four of them found no advantages in performing early 
anticoagulation therapy compared with a low-antiplatelet regimen. Colli et al. (2013) 
demonstrated higher morbidity in patients using VKA after bioprosthetic aortic valve 
replacement. Other recent studies comparing early to no anticoagulation have reported 
no signifi cant diff erence in bleeding episodes and no reduction in thromboembolism 
(9, 18). Elbardassi et al. and Jamieson et al. even suggested that early antithrombotic 
therapy had no benefi cial eff ect in patients without risk factors (19, 20). As a result, since 
most studies have been either retrospective or underpowered, the thrombotic prophy-
laxis after bioprosthetic aortic valve replacement remains controversial. The treatment 
policy of the VUmc, based on current guidelines, was changed in 2011 and now advises 
the use of aspirin instead of VKA in patients without risk factors (2).
In contrast to the fi ndings by Goldsmith et al., age, hypertension, diabetes, dyslip-
idemia, a history of smoking and left ventricular function were no predictors of post-
operative thromboembolic events (21). In our study only prior use of acenocoumarol 
was found to be a predictive risk factor for thromboembolic events. Those who received 
acenocoumarol before operation may have been more sensitive to thromboembolism 
by other risk factors, mostly atrial fi brillation.
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Most studies have found no significant differences in thromboembolic events or bleed-
ing complications between patients treated with anticoagulation therapy and patients 
treated with an antiplatelet regimen, whereas our study demonstrated that antiplatelet 
therapy has an apparent safety benefit in the first year after bioprosthetic aortic valve 
replacement and that this does not come with an increased thromboembolic risk. Still, 
in this uncontrolled setting, there could have been unknown risk factors that may have 
influenced these results. Nevertheless, our results indicate that aspirin should be consid-
ered the preferred antithrombotic regimen compared to acenocoumarol. This is in line 
with the recommendations of aspirin use after bioprosthetic aortic valve replacement 
by the AHA/ACC, ACCP, ESC and EACTS guidelines. Moreover, we think that our findings 
suggest that AHA/ACC and EACTS should revisit the recommendation of vitamin K an-
tagonists as an acceptable alternative. This recommendation of the ACC/AHA guidelines 
is based on a recent retrospective study that demonstrated a clear benefit associated 
with warfarin versus no warfarin during the initial three months after surgery (8). These 
findings, however, are based on different study populations. In our study two more 
homogenous groups could be compared. The beneficial effect of aspirin compared to 
no treatment at all cannot be answered from the results of our study.
Strength of our study is the fact that we included a cohort of consecutive patients with 
a fixed regime of antithrombotic prophylaxis prior to and after the change in the local 
antithrombotic policy in July 2011. In our study all surgeons and cardiologists strictly 
adhered to both guidelines before and after July 2011. We think this adds to the external 
validation of our findings. Surprisingly, the number of bleeding events before and after 
policy change did not differ significantly. This might be due to the larger number of 
patients using acenocoumarol preoperatively, which is a predictor for bleeding, after 
policy change in 2011. However, when comparing the number of days on aspirin versus 
acenocoumarol bleeding events were significantly lower in the aspirin group. The num-
ber of thromboembolic events was similar in both analyses. Our study had the inherent 
limitations of being retrospective. Treatment was not randomly allocated. Second, 
medical files were mostly but not entirely complete. Ideally, future randomized clini-
Table 7. Summary of findings: Antiplatelet versus anticoagulation therapy after bioprosthetic aortic valve 
replacement (5-7, 16, 17)
author, year Study design, follow up Conclusion
Blair et al. 1994 Retrospective, 3 months No significant differences
Gherli et al. 2004 Prospective observational, 3 months No significant differences
Aramendi et al. 2005 Prospective, 6 months No significant differences
Colli et al. 2007 Prospective, 3 months No significant differences
Colli et al. 2013 Prospective, 6 months Higher morbidity within 6 months using VKA
note: VKA= vitamin K antagonists
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cal trials comparing aspirin with VKA therapy are necessary to provide evidence-based 
recommendations for the implementation of optimal antithrombotic strategy.
In conclusion, our study shows a beneficial effect of aspirin compared to acenocouma-
rol one year after bioprosthetic aortic valve replacement, which reinforces the recom-
mendation of aspirin by current guidelines.
76 Chapter 5
RefeRenCeS
 1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, III, Guyton RA, et al. 2014 AHA/ACC 
guideline for the management of patients with valvular heart disease: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac 
Cardiovasc Surg 2014 Jul;148(1):e1-e132.
 2. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, et al. Guideline on antiplatelet 
and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008 Jul;34(1):73-
92.
 3. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. (Guidelines 
on the management of valvular heart disease (version 2012). The Joint Task Force on the Manage-
ment of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European 
Association for Cardio-Thoracic Surgery (EACTS)). G Ital Cardiol (Rome) 2013 Mar;14(3):167-214.
 4. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy 
for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American 
College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 Feb;141(2 
Suppl):e576S-e600S.
 5. Aramendi JI, Mestres CA, Martinez-Leon J, Campos V, Munoz G, Navas C. Triflusal versus oral anti-
coagulation for primary prevention of thromboembolism after bioprosthetic valve replacement 
(trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005 May;27(5):854-
60.
 6. Blair KL, Hatton AC, White WD, Smith LR, Lowe JE, Wolfe WG, et al. Comparison of anticoagulation 
regimens after Carpentier-Edwards aortic or mitral valve replacement. Circulation 1994 Nov;90(5 
Pt 2):II214-II219.
 7. Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve 
replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic 
pilot trial. J Heart Valve Dis 2007 Nov;16(6):667-71.
 8. Merie C, Kober L, Skov OP, Andersson C, Gislason G, Skov JJ, et al. Association of warfarin therapy 
duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic 
complications, and bleeding. JAMA 2012 Nov 28;308(20):2118-25.
 9. Moinuddeen K, Quin J, Shaw R, Dewar M, Tellides G, Kopf G, et al. Anticoagulation is unnecessary 
after biological aortic valve replacement. Circulation 1998 Nov 10;98(19 Suppl):II95-II98.
 10. Nowell J, Jahangiri M. Antiplatelet therapy after bioprosthetic aortic valve replacement is un-
necessary in patients without thromboembolic risk. Eur J Cardiothorac Surg 2007 Dec;32(6):945.
 11. Bekker MW, Noyez L, van Swieten HA. Anticoagulation therapy after bioprosthetic aortic valve 
replacement in Dutch cardiothoracic centres: acceptance of guidelines does not lead to overall 
implementationdagger. Interact Cardiovasc Thorac Surg 2015 Mar; 20 (3): 395-8.
 12. Colli A, Verhoye JP, Heijmen R, Strauch JT, Hyde JA, Pagano D, et al. Antithrombotic therapy after 
bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg 
2008 Apr;33(4):531-6.
 13. Hosmane S, Birla R, Marchbank A. Current practice of antiplatelet and anticoagulation manage-
ment in post-cardiac surgery patients: a national audit. Interact Cardiovasc Thorac Surg 2012 
Apr;14(4):474-5.
 14. Nowell J, Jahangiri M. Anticoagulation after bioprosthetic aortic valve replacement. J Thorac 
Cardiovasc Surg 2010 Nov;140(5):1201-2.
Antithrombotic strategy after bioprosthetic aortic valve replacement 77
 15. Edmunds LH, Jr., Cohn LH, Weisel RD. Guidelines for reporting morbidity and mortality after 
cardiac valvular operations. J Thorac Cardiovasc Surg 1988 Sep;96(3):351-3.
 16. Colli A, Verhoye JP, Heijmen R, Antunes M. Low-dose acetyl salicylic acid versus oral anticoagula-
tion after bioprosthetic aortic valve replacement. Final report of the ACTION registry. Int J Cardiol 
2013 Sep 30;168(2):1229-36.
 17. Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, et al. Comparing warfarin with aspirin 
after biological aortic valve replacement: a prospective study. Circulation 2004 Aug 3;110(5):496-
500.
 18. Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG, et al. Is early anticoagulation 
with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 
2005 May;129(5):1024-31.
 19. ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early antithrombotic therapy 
necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardio-
vasc Surg 2010 May;139(5):1137-45.
 20. Jamieson WR, Moffatt-Bruce SD, Skarsgard P, Hadi MA, Ye J, Fradet GJ, et al. Early antithrombotic 
therapy for aortic valve bioprostheses: is there an indication for routine use? Ann Thorac Surg 
2007 Feb;83(2):549-56.




Antithrombotic therapy after mitral 
valve repair – VKA or aspirin?
S.J. van der Wall, J.R Olsthoorn, S. Heuts, R.J.M. Klautz, A. Tomsic, E.K. Jansen,
A.B.A Vonk, P. Sardari Nia, F.A. Klok, M.V. Huisman




The optimal antithrombotic therapy following mitral valve repair (MVr) is still a matter 
of debate. Therefore, we evaluated the rate of thromboembolic and bleeding complica-
tions of two antithrombotic prevention strategies: vitamin K antagonists (VKA) versus 
aspirin.
Methods
Consecutive patients who underwent MVr between 2004 and 2016 at three Dutch 
hospitals were evaluated for thromboembolic and bleeding complications during three 
postoperative months. The primary endpoint was the combined incidence of thrombo-
embolic and bleeding complications to determine the net clinical benefit of VKA strategy 
as compared with aspirin. Secondary objectives were to evaluate both thromboembolic 
and bleeding rates separately and to identify predictors for both complications.
Results
A total of 469 patients were analyzed, of whom 325 patients (69%) in the VKA group 
and 144 patients (31%) in the aspirin group. Three months postoperatively, the cumula-
tive incidence of the combined end point of the study was 9.2% (95%CI 6.1-12) in the 
VKA group and 11% (95%CI 6.0-17) in the aspirin group (adjusted hazard ratio (HR): 1.6, 
95%CI 0.83-3.1). Moreover, no significant differences were observed in thromboembolic 
rates (adjusted HR: 0.82, 95%CI 0.16-4.2) as well as in major bleeding rates (adjusted HR: 
1.89, 95%CI 0.90-3.9).
Conclusions
VKA and aspirin therapy showed a similar event rate of 10% during three months after 
MVr in patients without prior history of AF. In both treatment groups thromboembolic 
event rate was low and major bleeding rates were comparable. Future prospective, ran-
domized trials are warranted to corroborate our findings.
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InTRoduCTIon
Mitral valve repair (MVr) is recognized as the gold standard for degenerative mitral regur-
gitation. Compared to mitral valve replacement, repair results in improved survival, bet-
ter preservation of postoperative left ventricular function and avoidance of the need for 
long-term anticoagulation treatment (1,2). The risk of thromboembolic events following 
MVr varies from 0.4% to 1.6 % per year, and reaches 2.5% during the first postoperative 
month, even with routine anticoagulation therapy (3,4). However, the appropriate an-
tithrombotic therapy following MVr is still a subject of controversy. Recommendations 
from international guidelines for the postoperative antithrombotic management have 
been controversial (5-7), and are based on observational studies without conclusive 
results, or are provided without references supporting the recommendation (4,8-11).
Consequently, antithrombotic prophylaxis for the prevention of thrombotic events 
early after MVr varies widely among cardio-thoracic surgeons with a vitamin K antagonist 
(VKA) prescription varying from 46% to 64% in patients with sinus rhythm (12,13). The 
risk of thromboembolism secondary to a high incidence of new onset atrial fibrillation 
(AF) postoperatively and the thrombogenic tendency of the non-endothelialized repair 
components could motivate surgeons and cardiologists to prescribe VKA therapy for the 
first months after MVr (14). However, evidence is limited and more accurate knowledge 
of the postoperative antithrombotic treatment is required. Based on recent literature 
and anecdotal reports, we hypothesized that VKA treatment is associated with an in-
creased risk of major bleeding events and no reduction in thromboembolic events (18).
We set out to perform a retrospective observational study to evaluate the rate of 
thromboembolic and bleeding and complications of two antithrombotic prevention 
strategies – one with VKA and one with aspirin – occurring within the first three postop-
erative months.
MaTeRIaL and MeThodS
Study design and patients
This study was a retrospective observational multicentre cohort study of consecutive 
adult patients who underwent MVr, to evaluate thromboembolic and bleeding compli-
cations of two antithrombotic strategies, VKA and aspirin. Data were collected from the 
databases of the departments of cardiothoracic surgery of the Leiden University Medical 
Centre (LUMC), VU University medical centre (VUmc) and Maastricht University Medi-
cal Centre (MUMC). Patients, who underwent a first MVr with or without concomitant 
tricuspid valve repair (TVr) between 2004-2016 in these three centres, were eligible. The 
post-operative care of these patients often took place in one of 16 affiliated regional 
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hospitals, in which all postoperative medical files were scrutinized for primary and 
secondary endpoints. Patients were excluded when they underwent other concomitant 
cardiac procedures than TVr, had previous cardiac surgery or were diagnosed with AF 
preoperatively. Other concomitant procedures were excluded because these lead to 
more heterogeneous patient groups. The institutional review board of the LUMC, VUmc 
and MUMC approved the study protocol and waived the need for informed consent due 
to the observational design.
Procedures and treatment
MVr was performed at the department of cardiothoracic surgery at the LUMC, VUmc or 
MUMC and involved implantation of an annuloplasty ring (Edwards Physio I or II mitral 
ring, Carpentier-Edwards Classic Annuloplasty Ring or Duran AnCore Ring for MVr, and 
Edwards MC3 tricuspid ring or Carpentier-Edwards Classic Annuloplasty Ring in case of 
concomitant TVr, Edwards Lifesiences/Medtronic, USA), and various concomitant tech-
niques (leaflet resections, artificial chorda tendinae implant, chordal transposition, or 
edge-to-edge technique).
Group A comprised patients from the LUMC and VUmc hospitals, in which therapeutic 
doses of low-molecular-weight heparin (LMWH) nadroparin were given on the first 
postoperative day at 7600IU/day for patients < 50 kg, 11.400 IU/day for patients 50-
70 kg, 15.200 IU/day for patients 70-100 kg and 19.000 IU/day for patients > 100 kg 
simultaneously with VKA. Treatment with nadroparin was continued until a VKA reached 
therapeutic levels, as shown by an international normalized ratio (INR) >2.0 on two 
consecutive days. VKA therapy was maintained for six to twelve weeks postoperatively 
and then discontinued at the discretion of the referring cardiologist and occasionally 
switched to aspirin. The target INR during VKA treatment was 2.0-3.0.
Group B consisted of patients from the MUMC hospital, in which prophylactic doses of 
nadroparin were started on the first postoperative day at 3750IU/day for patients <80kg, 
5700 IU/day for patients 80-100 kg and 7600IU/day for patients > 100 kg simultane-
ously with aspirin 80mg once daily which was continued lifelong in patients with sinus 
rhythm. Nadroparin was stopped as soon as the patient was fully mobilized. In case of 
postoperative new onset AF that sustained for more than 24 hours, nadroparin and VKA 
were started analogous to the antithrombotic strategy used in the LUMC and VUmc.
Study endpoints
The primary endpoint of this study was the combined incidence of thromboembolic 
and major bleeding complications three months following MVr. This double endpoint 
was the basis for determining the net clinical benefit of VKA as compared with aspirin. 
Since we anticipated a high incidence of postoperative new onset AF, we also compared 
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the primary endpoint in patients who did not develop AF during follow-up as well as in 
patients who received treatment according to the preferred strategy.
Secondary objectives were to evaluate the incidence rates of thromboembolic and 
major bleeding events separately and to identify predictors for bleeding and thrombotic 
complications. All thromboembolic and bleeding events were classified using the criteria 
for reporting mortality and morbidity after cardiac valve interventions respectively and 
those of the International Society on Thrombosis and Haemostasis respectively (15,16). 
Thromboembolic and bleeding complications occurring on the first postoperative day 
were not taken into consideration because both antithrombotic therapies were started 
this day. All suspected bleeding events were independently adjudicated by two expert 
physicians (F.K. and M.V.) who were blinded to treatment assignment. Disagreement was 
resolved by consensus.
Predefined candidate predictors for thromboembolic and bleeding events were de-
fined according to the documentation provided by the treating physician, e.g. age, sex, 
prior arterial or venous thromboembolism, prior PCI, hypertension, history of smoking, 
preoperative use of anticoagulation therapy, left ventricular ejection fraction (LVEF), 
concomitant TVr, repeat thoracotomy and new onset AF. The cause of death was veri-
fied by reviewing the pathology report. In case autopsy had not been performed, the 
likely cause of death was verified with the treating physician. All patients were followed 
and censored at a maximum follow up period of three months, the date of last chart 
documentation, reoperation or outcome events, whichever came first.
Statistical analyses
Means (standard deviation (SD)) and medians (interquartile range (IQR)) to present 
baseline continuous baseline variables were used. For categorical variables, frequencies 
and percentages were used. Pearson’s χ2 test was used to compare the distribution of 
categorical variables, whereas the independent t-tests were used for normally distrib-
uted continuous variables. For analysis of primary and secondary objectives, cumulative 
incidences of bleeding and thromboembolic events of both antithrombotic strategies 
were estimated according to the Kaplan-Meier methods and presented with two-sided 
95% confidence intervals (CI). A Cox proportional hazard model was used to compare 
both strategies, adjusted for age, gender, and baseline differences.
Backward conditional multivariate Cox-regressions analysis was used to evaluate 
possible predictors for thrombotic and bleeding events, using variables of clinical im-
portance (age and gender) or that were identified to be relevant predictors (P<0.1) in 
univariate analysis. Data were analyzed using SPSS version 23 (SPSS, Chicago, IL, USA). A 




In the three participating cardiothoracic surgical centers, 809 patients underwent a first 
isolated MVr between 2004 and 2016. Of these patients, 340 (42%) were excluded for 
the following reasons: 109 did not receive treatment in one of the affiliated regional 
hospitals postoperatively (4.9%), 224 had preoperative AF (10%) and seven patients 
were lost to follow up (0.32%). The remaining 469 (21%) patients were included; 325 
patients (69%) in group A and 144 patients (31%) in group B. The baseline characteristics 
of both groups are shown in Table 1. Their mean age was 61 (SD 12) and 280 patients 
(60%) were men. Patients in group A underwent concomitant TVr more frequently (22% 
vs. 4.9%). In group B, a LVEF below 40% and preoperative aspirin use were more present 
(9% vs. 3.8% and 27% vs. 18% respectively). A total of 220 patients (47%) developed new 
onset AF after surgery and 35 patients (7.5%) required a repeat thoracotomy.






Age at operation, mean ± SD 60 ± 13 62 ± 11
Male, n (%) 195 (60) 85 (59)
Prior ischemic stroke, n (%) 7 (2.2) 8 (5.6)
Prior MI, n (%) 12 (3.7) 4 (2.8)
Prior PCI, n (%) 11 (3.4) 5 (3.5)
Prior VTE, n (%) 11 (3.5) 2 (2.6)
LV ejection fraction <40%, n (%) 12 (3.8) 13 (9)*
Diabetes, n (%) 17 (5.4) 5 (3.5)
Hypertension, n (%) 149 (47) 74 (51)
COPD, n (%) 29 (8.9) 15 (10)
History of smoking, n (%) 99 (31) 27 (19)
Preoperative anticoagulation use, n (%)
VKA 12 (3.7) 4 (2.8)
Aspirin 57 (18) 39 (27)*
Clopidogrel 3 (0.90) 2 (1.4)
Dual AP 1 (0.30) 2 (1.4)
Active endocarditis at the moment of surgery, n (%) 24 (7.4) 9 (6.3)
Concomitant TVr, n (%) 72 (22) 7 (4.9)*
note: SD = Standard Deviation, MI = Myocardial infarction, PCI = Percutaneous Coronary Intervention, VTE 
= Venous Thromboembolic Event, LV = Left Ventricular, VKA=Vitamin K Antagonist, AP=Antiplatelet, TVr = 
Tricuspid Valve Repair, *P-value below 0.05
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antithrombotic treatment
Of the 325 patients in group A, 319 patients (98%) were treated with VKA therapy, four 
(1.2%) with aspirin therapy and one patient (0.31%) with LMWH (figure 1a). In group 
B, 92 of the 144 patients (64%) received aspirin, 46 patients (32%) VKA because of new 
onset AF and six patients (4.2%) received other antithrombotic therapy than VKA or 
aspirin (figure 1b). Twenty-three patients (25%) in group B, who received initial aspirin 
therapy, experienced a single episode of new onset AF.












































































note: 11, 28, 31 patients censored for other reasons than study endpoints. *Data missing in 16 patients. $2 




Table 2 shows the incidence of thromboembolic and bleeding events in each study 
group. The primary end point of the study – the composite of thromboembolic and 
bleeding events – was reached in 29/325 patients in group A (cumulative incidence: 
9.2%, 95%CI 6.1-12) and in 16/144 patients in group B (cumulative incidence: 11%, 
95%CI 6.0-17; adjusted hazard ratio (HR): 1.6, 95%CI 0.83-3.1). The composite of throm-
boembolic and bleeding events in patients without new onset AF occurred in 14/177 
patients (cumulative incidence: 8.2%, 95%CI 4.1-12) in group A and 5/72 patients in 
group B (cumulative incidence: 8.1%, 95%CI 2.0-14.2; adjusted HR: 0.97, 95%CI 0.32-2.9). 
In patients who received initial treatment according to the preferable strategy, 28/319 
patients experienced the primary endpoint in group A and 6/92 patients in group B 
during the first three months, for a cumulative incidence of 9.0% (95%CI 5.9-12) and 
6.6% (95%CI 1.5-12) respectively (adjusted HR: 0.90, 95% CI: 0.35-2.3).
Thromboembolism and bleeding
A total of 8/325 thromboembolic events occurred in group A after a median duration of 
9 days (IQ 3.3-15) and 2/144 in group B after a median duration of 50 days (IQR 45-50), 
for a respective cumulative incidence of 2.6% (95%CI 0.84-4.4) and 1.6% (95%CI 0-3.8; 
adjusted HR: 0.82, 95%CI 0.16-4.2). 21/325 patients experienced a major bleeding in 
group A after a median duration of 12 days (IQR 8-15) and 14/144 patients in group B 







Major bleeding 21 (6.8)§ 14 (9.1)
Site
Chest 20 12
GI tract 0 1
Unknown 1 1
Fatal bleeding 1 1
Thromboembolic events 8 (2.6) 2 (1.6)
Type
Ischemic stroke 4 1
TIA 4 0
Left atrial thrombus 0 1
Fatal ischemic stroke 0 1
note: GI = Gastrointestinal, TIA = Transient Ischemic Attack, MI = Myocardial infarction, DVT = Deep Venous 
Thrombosis
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after a median duration of 11 days (IQR 4.8-20), for cumulative incidences of 6.8% (95%CI 
4.1-9.5) and 9.1% (95%CI 4.2-14) respectively (adjusted HR: 1.89, 95%CI 0.90-3.9). A total 
of 89% of the major bleeding events were pericardial tamponades, of which two were 
fatal (one in each group).
other observations
During the study period, four patients died (cumulative incidence: 0.9%, 95%CI 0-1.9), 
of whom two died in group A and two in group B. Causes of death were pericardial 
tamponades (two patients), ischemic stroke and cardiac arrest.
Predictors for thromboembolism and major bleeding
Uni- and multivariate analysis of predictors for thromboembolic and major bleeding 
events in patients who received initial treatment according to antithrombotic strategy 
are shown in Table 3. Multivariate analysis revealed that only concomitant TVr was 
independently associated with an increased risk of bleeding events (odds ratio (OR): 2.8, 
95%CI 1.4-5.7) for both groups. For thromboembolic events, no independent predictors 
were found by multivariate analysis.











Age >60 0.94 (0.48-1.8) 0.71 (0.21-2.4)
Female 1.2 (0.64-2.4) 0.37 (0.78-1.7)
Prior ischemic stroke - 3.1 (0.39-25)
Prior MI 0.84 (0.12-6.1) -
Prior PCI 0.80 (0.11-5.8) -
Prior VTE 1.1 (0.15-8.0) -
LV ejection fraction < 40% 2.2 (0.78-6.3) -
Diabetes 1.9 (0.59-6.3) -
Hypertension 1.2 (0.62-2.3) 2.3 (0.61-9.1)
History of smoking 0.78 (0.36-1.7) 1.5 (0.46-5.3)
New onset AF 1.7 (0.88-3.4) 1.1 (0.33-4.0)
Concomitant TVr 2.8 (1.4-5.7) 2.8 (1.4-5.7) 2.3 (0.59-8.9)
Active endocarditis 1.7 (0.6-4.8) 1.5 (0.19-11)
note: MI = Myocardial infarction, PCI = Percutaneous Coronary Intervention, VTE = Venous Thromboem-
bolic Event, LV = Left Ventricular, AF = Atrial Fibrillation, TVr = Tricuspid Valve Repair
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dISCuSSIon
VKA and aspirin therapy showed a similar event rate of 10% during the first three months 
after MVr in patients without prior history of AF. In both treatment groups thromboem-
bolic event rate was low and major bleeding rates were comparable.
Nearly all bleedings occurred soon after surgery, particularly during the first two 
weeks after MVr. Interestingly, most of these were pericardial tamponades that required 
repeat thoracotomy. In contrast, the thromboembolic events occurred more dispersed 
throughout the first three months.
VKa versus aspirin treatment
We chose a primary combined endpoint of thromboembolic and bleeding rates be-
cause both events would have a comparable prognostic effect as both represent an 
important cause of death and disability after heart valve surgery (17). A comparison 
between VKA strategy (group A) and aspirin strategy (group B) revealed no difference 
in the combined outcome of thromboembolic and bleeding complications as well as 
for both outcomes separately occurring within three months after MVr. As expected, 
a third of the patients in group B could not follow the aspirin strategy because of new 
onset AF and received VKA treatment instead of aspirin therapy. Both of these group 
B treatment groups experienced major bleeding events to a similar extent. However, 
after exclusion of AF patients in the entire study population as well as analysing patients 
who received treatment according to the preferable strategy, again no difference in the 
combined endpoint was found, despite a group B population with solely aspirin use. Of 
note, three thromboembolic events in the VKA group occurred within the first four days 
during which VKA treatment still had not yet reached therapeutic levels. The observed 
three-month cumulative incidence for thromboembolic events is in aligned with those 
reported by previous studies (18,4). The observed incidence of major bleeding events 
was slightly higher than described in previous reports, probably due to the adjudication 
process of postoperative pericardial tamponade (19,20). Pericardial effusion alongside 
signs of hemodynamic instability was adjudicated as a pericardial bleeding, whereas 
these events might not be considered as (major) bleedings in previous studies.
Perspective of international guidelines
Recommendations from international guidelines are contradictory to our results, 
favouring either VKA or aspirin as postoperative thromboprophylaxis three months 
after MVr (6,21,5). Three former retrospective studies have compared antiplatelet with 
anticoagulation therapy in patients after MVr (8,22,20,19). Two studies found no differ-
ences in stroke and bleeding rate of early VKA treatment compared with aspirin therapy, 
suggesting that VKA treatment might not be necessary (22,20). The largest study to date 
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by Paparella et al (19) found less bleeding and comparable arterial thromboembolic 
events in patients treated with aspirin six months following MVr. However, in contrast to 
our study, no data on AF were reported and assigned treatment was mainly chosen by 
the surgeons’ preference. A small study by Aramendi et al (8) found a beneficial effect 
of antiplatelet therapy in preventing thromboembolic events compared with VKA treat-
ment with no increased risk of bleeding. Thus, these four studies suggest aspirin use 
after MVr. This contradicts the recommendation of VKA use over aspirin by the American 
College of Cardiology/American Heart Association (ACC/AHA) and European Society 
of Cardiology/European Association of Cardiothoracic Surgery (ESC/EACTS) guidelines 
(6,21). The ACC/AHA recommendations are based on one observational cohort study 
which found a high 30-day ischemic stroke incidence of 1.5%, despite VKA treatment 
(21,4). The ESC recommendation is provided without references, illustrating the paucity 
of information (6). Since recommendations from guidelines are based on retrospec-
tive and underpowered studies, the optimal thromboprophylaxis after MVr remains 
controversial and a frequent matter of debate. However, based on the scarcity of data, 
our results might suggest a reassessment of the recommendations from international 
guidelines.
Predictors
In our study, only concomitant TVr was found to be an independent predictor for major 
bleeding events. Concomitant TVr might have been a more difficult procedure with 
prolonged cardiopulmonary bypass duration, leading to dysfunction of platelets, which 
is associated with major cause of excessive bleeding in the early postoperative period 
(23,24). Other not predefined predictors, such as surgery duration, preoperative hema-
tologic laboratory values and surgical techniques might also have contributed to the 
occurrence of early bleeding events. Consistently with earlier findings, no independent 
predictors were found for thromboembolic events (18).
Clinical perspective
When considering the appropriate antithrombotic treatment after MVr, the thrombotic 
risk secondary to the endothelialization process and new onset AF could be a good 
rationale for physicians to prescribe VKA treatment. During the first three postoperative 
months, the exposure of circulating blood to non-endothelialized repair components 
can cause thrombus formation and even endocarditis, particularly due to a relatively 
slower blood flow in the left atrium compared to other parts of the heart. AF is a com-
mon postoperative cardiac arrhythmia after MVr occurring in approximately 24-35% of 
the patients, even after two postoperative weeks (25,14). In this study we found this 
incidence of new onset AF to be 47%. VKA treatment, however, has many disadvantages, 
including need for frequent laboratory monitoring, variability of dose response and 
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drug and food interactions while in contrast aspirin does not require monitoring and 
dosage adjustments. Consequently, for practical reasons, aspirin might be preferable 
as antithrombotic treatment compared to VKA in patients with sinus rhythm. Therefore, 
the choice of antithrombotic treatment in patients without prior history of AF should be 
individualized based on patient-specific considerations, such as risk factors for AF, com-
pliance with treatment and frailty. Despite the lack of prospective studies specifically 
evaluating treatment with direct oral anticoagulants (DOACs) in patients with mitral 
valve repair, subanalysis of DOAC AF trails have showed a similar overall efficacy and 
safety as compared with VKA in patients with valvular heart disease, including mitral 
valve repair (26). However, international guidelines do not recommend the use of DO-
ACs during the first three to six postoperative months in patients with AF (5-7).Future 
prospective randomized trials are warranted to provide conclusive results about DOAC 
treatment in the early postoperative phase after mitral valve repair in patients with and 
without AF.
Strengths and limitations
The strength of this study is the large cohort of consecutive patients providing novel 
and clinically relevant data on the antithrombotic strategy after MVr. Moreover, the 
study population was rather homogeneous due to the exclusion of concomitant pro-
cedures that might lead to different patient groups (i.e. AF, other valve and coronary 
atherosclerotic surgery).
Our study had several limitations as well. First, a direct comparison between patients 
treated with VKA and aspirin would have been preferable but the high incidence of AF 
makes such a trial difficult to perform. A large number of patients would be required, 
in particular patients receiving aspirin. Second, antithrombotic treatment was not 
randomly allocated due to the retrospective study design. Third, no data was available 
on individual INR measurements and thus the time during which VKA treated patients 
were in therapeutic range is unclear. Fourth, we performed a multi-centre study with 
inherent perioperative variabilities. Ideally, future prospective, randomized clinical trials 
are warranted to provide evidence-based recommendations for the implementation of 
appropriate antithrombotic strategy after MVr.
In conclusion, VKA and aspirin therapy showed a similar event rate of 10% during 
three months after MVr in patients without prior history of AF. In both treatment groups 
thromboembolic event rate was low and major bleeding rates were comparable. Future 
prospective, randomized trials are warranted to corroborate our findings.
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Because practice-based data on the usage of idarucizumab for urgent dabigatran 
reversal are unavailable we evaluated the appropriateness of idarucizumab usage, its 
hemostatic effectiveness and clinical outcomes.
Methods
An observational cohort study was performed including consecutive patients who were 
treated with idarucizumab between 2016 and 2018. Appropriate usage was assessed 
with predefined criteria. Post-reversal effectiveness was evaluated according to ISTH 
recommendations. Patients were followed for 90 days for occurrence of thromboembo-
lism, (re-)bleeding and death.
Results
Idarucizumab was used in 88 patients, of whom 53 (60%) presented with severe bleed-
ing (20 gastrointestinal and 18 intracranial) and 35 (40%) requiring urgent surgical 
intervention. Use of idarucizumab was judged inappropriate in 25 patients (28%). Effec-
tive hemostasis was achieved in 32 of 48 (67%) bleeding patients in whom assessment 
was possible. Seven of 16 patients with major bleeding who did not achieve effective 
hemostasis (five intracranial) died, compared to two of 32 patients with effective hemo-
stasis (relative risk: 7.0, 95% confidence interval 1.6-30). Four patients (4.2%) developed 
thromboembolism (2 (2.1%) within 30 days) and four patients (4.2%) re-bleeding, all 
within 10 days. Seventeen patients (19%) died; 10 (11%) within five days.
Conclusion
In this practice-based cohort, idarucizumab use was considered inappropriate in 28% of 
patients. Effective hemostasis was achieved in two third of bleeding patients and was 
associated with lower mortality risk. Clinical outcomes were similar to those observed in 
the RE-VERSE AD trial, comprising re-bleeds and thromboembolism, and a high mortal-
ity rate.
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InTRoduCTIon
Because of its favourable benefit-risk profile compared to vitamin K antagonists (VKA), 
dabigatran etexilate (Pradaxa®) is widely used for the prevention of ischemic stroke in 
patients with non-valvular atrial fibrillation and for the prevention and treatment of 
venous thromboembolism (1, 2). However, as for all anticoagulants, bleeding, including 
life-threatening or fatal bleeding, remains a relevant side effect. The lack of a reversal 
agent has been perceived as a concern to both patients and clinicians which until re-
cently has been an obstacle for direct oral anticoagulant (DOAC) use in many patients.
The specific reversal agent Idarucizumab (Praxbind®), a monoclonal antibody frag-
ment that binds dabigatran with high affinity, has been approved by the U.S. Food and 
Drug Administration and the European Medicines Agency for urgent dabigatran reversal 
(3-5). This approval was based on the results of the Reversal Effects of Idarucizumab 
on Active Dabigatran (RE-VERSE AD) trial which showed rapid and complete reversal of 
dabigatran activity in patients with uncontrolled or life-threatening bleeding or under-
going an emergency procedure (6). Further insight on the clinical use of idarucizumab is 
only available from case reports and one small retrospective study demonstrating safe 
and effective idarucizumab administration in 31 patients with intracranial bleeding or 
ischemic stroke prior to thrombolysis (7, 8). Even so, current international guidelines 
recommend idarucizumab usage for urgent dabigatran reversal in the presence of life-
threatening bleeding or urgent surgery associated with high risk of bleeding (9, 10). It 
remains nonetheless to the clinician’s discretion to decide in which clinical setting usage 
of idarucizumab is appropriate.
Since data on idarucizumab in daily practice are scarce, we set out to perform an 
observational study aiming to determine the appropriateness of idarucizumab usage as 
well as the hemostatic effectiveness and clinical outcomes in daily practice.
MeThodS
Study design and population
This was an observational, multicentre cohort study including consecutive patients who 
were treated with idarucizumab between 2016 and 2018, with the aim of evaluating ap-
propriate usage, hemostatic effectiveness and 90-day clinical outcomes. A representa-
tive from manufacturer Boehringer Ingelheim provided a list of 20 major idarucizumab 
distributing Dutch hospital pharmacies which were all approached for participation. 
Five of them replied not to have dispensed idarucizumab, three did not comply with the 
request and 12 provided all available information. Subsequently, data were collected 
by scrutinizing medical records, including medical notes, laboratory results, radiology 
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reports and other relevant details. No exclusion criteria were applied. The institutional 
review board of the LUMC centrally approved the study and waived the need for in-
formed consent because of its observational non-interventional design.
Study outcomes
The primary objective was to assess the appropriateness of idarucizumab usage. Each 
individual administration was adjudicated independently by two expert physicians (F.K. 
and M.V.) using criteria listed in Table 1. These criteria were predefined and based on an 
expert consensus of the International Society on Thrombosis and Haemostasis (ISTH) for 
reversal of direct oral anticoagulants (DOACs) (11). These guidance indications include 
life-threatening/uncontrollable bleeding, bleeding into a critical organ or closed space, 
prolonged bleeding despite local hemostatic measures, high risk of recurrent bleeding 
because of overdose or delayed clearance of dabigatran, and need for an urgent inter-
vention associated with a high risk of bleeding.
In line with the RE-VERSE AD trial (6), bleeding was considered uncontrollable if one or 
more of the following criteria were met: symptomatic intracranial bleeding, a reduction 
in hemoglobin (Hb) of at least 5 g/dL, transfusion of at least 4 units of blood or packed 
cells, bleeding requiring use of intravenous inotropic agents or necessitating surgical 
intervention. An urgent intervention was defined as one that could not be delayed for 
at least 8 hours. We added indicators for the presence of dabigatran plasma levels as a 
criterion for appropriateness. These indicators comprised a sensitive activated Partial 
Thromboplastin Time (aPTT), diluted Thrombin Time (dTT) or ecarin clotting time (ECT) 
laboratory test result above the upper limit of normal (according to fixed cut-off points 
of individual hospitals) and/or a self-reported time of last dabigatran intake. Discrepan-
cies were resolved independently by a third party, consisting of a relevant specialized 
expert physician who was selected ad hoc.
Secondary objectives were 1) to assess hemostatic efficacy after administration for 
urgent reversal in bleeding events, and 2) to evaluate the incidence of 90-day clinical 
outcomes, comprising thromboembolism, (re-)bleeding and death. Hemostatic efficacy 
was assessed in accordance with standardized definitions published by the ISTH (12). 
Additional chart data were collected for bleeding course, need for blood products, 
additional procedures, and , for intracranial bleeding solely, results from repeat com-
puted tomography scans and change in neurological status. Thromboembolic events 
comprised objectively verified arterial (i.e. stroke, transient ischemic attack, myocardial 
infarction or arterial thromboembolism) or venous thromboembolisms (i.e. deep vein 
thrombosis and pulmonary embolism). Bleeding complications were classified using the 
ISTH criteria for major bleeding (13). The cause of death was verified by reviewing the 
pathology report. In case autopsy had not been performed, the likely cause of death was 
verified with the treating physician.
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Statistical analysis
Means (standard deviation (SD)) and medians (interquartile range (IQR)) were used to 
present continuous variables and analyzed with t-test for normal and the Mann-Whitney 
test for skewed distributions. The categorical variables were described by proportions 
(n) and percentages (%), and compared using relative risks (RRs) with associated 95% 
confidence intervals (CI). Data were analyzed using SPSS version 23 (SPSS, Chicago, IL, 
USA). A P-value below 0.05 was considered to be significant.
ReSuLTS
Study population
Demographic and clinical characteristics of all consecutive 88 patients who were treated 
with idarucizumab for urgent dabigatran reversal are listed in Table 2. Among the 12 
hospitals, the number of administrations varied from one to 14 during the two year 




appropriate usage Inappropriate usage
Intervention Proper indication ISTH guidance
Need for urgent intervention that cannot 
be delayed for drug clearance (within eight 
hours)
Emergency intervention in patients at high 
risk for procedural bleeding
Indicators for presence of circulating 
dabigatran
Dabigatran intake <72h
Prolonged aPTT, ECT or dTT*
Improper indication ISTH 
guidance
Intervention that can be delayed 
to permit dabigatran clearance
Elective surgery
Absence of indicators for 
circulation dabigatran
bleeding Proper Indication ISTH guidance
Uncontrollable hemorrhage
Closed space or critical organ (intraspinal, 
intraocular, pericardial, pulmonary, 
retroperitoneal, intramuscular with 
compartment syndrome
Persistent major bleeding or risk of recurrent 
bleeding because of delayed dabigatran 
clearance
Indicators for presence of circulation 
dabigatran
Dabigatran intake <72h
Prolonged aPTT, ECT or dTT*
Improper indication ISTH 
guidance
Major (GI) bleeds that respond to 
supportive measures
Absence of indicators for 
circulating dabigatran
note: ISTH=International Society on Thrombosis and Haemostasis, aPTT=activated Partial Thromboplastin 
Time, dTT=diluted Thrombin Time, ECT=ecarin clotting time, GI=Gastrointestinal.
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study period. Fifty-three (60%) patients presented with bleeding and 35 (40%) patients 
required urgent intervention. The mean age was 76 (SD ± 9) years and 51 patients (58%) 
were males. Nearly all patients (96%) had atrial fibrillation (AF) as primary indication 
for dabigatran use. The last self-reported dabigatran intake was > 24 hours in 11 pa-
tients (13%). Administration of idarucizumab occurred at the hospital ward (49%), the 
emergency room (34%), operating theatre (9.1%) or intensive care unit (6.8%). The aPTT 
was measured in 38 patients (43%) and was prolonged in 32/38 patients (84%). Specific 
dabigatran tests (ECT or dTT) were available in 10 of 12 included hospitals (83%) but 
were used in only 16 patients (18%). Of the 53 patients who presented with bleeding, 
Table 2. Baseline characteristics of 88 patients who received idarucizumab. Patient used *75mg dabigatran 
BID and †rivaroxaban.
Characteristic Intervention (n=35) bleeding (n=53) Total (n=88)
age, mean ± SD 74 ± 9 78 ± 9 76 ± 9
Male, no. (%) 19 (54) 32 (60) 51 (58)
eGfR (ml/ms), no. (%) >90 5 (14) 5 (9.4) 10 (11)
61-90 16 (46) 23 (43) 39 (44)
30-60 7 (20) 20 (38) 27 (31)
<30 5 (14) 3 (5.7) 8 (9.1)
Missing 2 (5.7) 2 (3.8) 4 (4.5)
dabigatran dosage 
bId, no. (%)
150mg 18 (52) 18 (34) 36 (41)
110mg 16 (46) 34 (64) 50 (57)
Other 1 (2.9)* 1 (1.9) † 2 (2.3)
dabigatran 
indication, no. (%)
AF 32 (91) 52 (98) 84 (96)
VTE 2 (5.7) 1 (1.9) 3 (3.4)
Unknown 1 (2.9) 0 1 (1.1)




<24 32 (91) 44 (83) 76 (86)
24-47 3 (8.6) 4 (7.5) 7 (8.0)
48-71 0 2 (3.8) 2 (2.3)
>72 0 2 (3.8) 2 (2.3)
Missing 0 1 (1.9) 1 (1.1)
Laboratory tests prior to idarucizumab administration
aPTT (s) No (%) 8 (22) 30 (57) 38 (43)
Above normal range, no (%) 8 (100) 24 (80) 32 (84)
dabigatran (eCT/
dTT) (s)
No (%) 8 (23) 8 (15) 16 (18)
> 30 ng ml-1 7 (88) 8 (100) 15 (94)
> 50 ng ml-1 5 (63) 7 (88) 12 (75)
note: eGFR=estimated Glomerular Filtration Rate, BID=Twice a day, AF=Atrial Fibrillation, VTE=Venous 
Thromboembolism, aPTT=activated Partial Thromboplastin Time, TT= Thrombin Time, dTT=diluted Throm-
bin Time, ECT=ecarin clotting time, NSAID=Non-Steroidal Anti-inflammatory Drugs, SSRI=Selective Sero-
tonin Reuptake Inhibitors
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most had gastrointestinal (38%) or intracranial bleeding (34%; Table 3). Of the 35 urgent 
interventions, most were performed in the abdominal region (39%). The time between 
administration of idarucizumab and initiation of intervention varied greatly (figure 1). 
Each patient received the recommended dosage of idarucizumab (single administration 
of two times 2.5 grams).
appropriateness of idarucizumab usage
Inappropriate usage of idarucizumab occurred in 25 patients (28%): 14 of 35 patients 
(40%) requiring intervention and 11 of 53 patients (21%) presenting with bleeding 
(Supplemental table S1). All 14 interventions could have been delayed for at least 
eight hours and eight of these 11 (72%) bleeding complications were not considered 
uncontrollable. Three bleeding patients (5.7%) had no dabigatran plasma levels; two 
had a last intake >72 hours as well as normalized aPTT levels, and one patient used 
figure 1. Time between first idarucizumab infusion and initiation of procedure in 31 patients in whom this 



















Time between administration and intervention
Table 3. Bleeding events and interventions of 88 patients who received idarucizumab. All data is presented 
as n (%).
Intervention (n=35) bleeding (n=53)
Abdominal 14 (40) Gastrointestinal 20 (38)
Cardiovascular 8 (23) Intracranial 18 (34)
Fractures 5 (14) Pericardial 7 (13)
Nervous system 3 (8.6) Lung 2 (3.8)
Skin 2 (5.7) Other 6 (11)
Lung 1 (2.9)
Eye 1 (2.9)
Pancreatic/hepatobiliary 1 (2.9) Traumatic 9 (17)
104 Chapter 7
rivaroxaban instead of dabigatran. Nearly all bleeding events in which the administra-
tion was considered inappropriate were located in the gastrointestinal tract (73%).
hemostatic effectiveness
Treatment with idarucizumab was considered effective in 32 of 48 (67%) bleeding 
patients in whom assessment was possible (Table 4). No significant difference was 
observed between the effectiveness of intracranial and extracranial bleeding (RR: 1.2, 
95%CI 0.53-2.7) as well as traumatic and non-traumatic bleeding (RR: 1.5, 95%CI 0.40-
6.1). Seven of 16 patients (44%) with bleeding (five intracranial) who did not achieve 
effective hemostasis died compared to two of 31 patients (6.5%) with effective hemosta-
sis (RR: 7.0, 95%CI 1.6-30). Effective hemostasis of appropriate idarucizumab usage was 
comparable to all administrations, achieved in 28 of 38 patients (74%).
CLInICaL ouTCoMeS
Thromboembolic and bleeding complications
Four thrombotic and four (re-)bleeding complications occurred during the 90-day fol-
low up, all in patients who initially had presented with bleeding (Table 5). Thrombotic 
events comprised two ischemic strokes, occurring on day one (before anticoagulation 
resumption) and 41 (after anticoagulation resumption), and two pulmonary embolisms 
(one fatal), occurring on day five (before anticoagulation resumption) and 21 (after dabi-
gatran resumption). A 65-year old male who developed ischemic stroke at the first day 
after idarucizumab administration also developed a major pericardial re-bleeding after 
six days after restart of anticoagulation therapy. Other re-bleeding events comprised 
Table 4. Effectiveness of hemostasis in 53 patients with bleeding events. *Other bleedings were: lung, ret-
roperitoneal, skin or fractures.
effective Ineffective unclear
bleeding type, n (%) GI bleeding 15 (75) 5 (25) 0
ICH 10 (56) 6 (33) 2 (11)
Pericardial 4 (57) 1 (14) 2 (29)
Other* 3 (38) 4 (50) 1 (13)
Traumatic 3 (33) 4 (44) 2 (22)
Non-traumatic 12 (29) 27 (64) 3 (7.1)
Mortality, n (%) 2 (6.3) 7 (44) 3 (60)
additional procedures, n (%) 9 (75) 2 (17) 1 (8.3)
days of hospital stay, mean (IQR) 9 (4-13) 10 (3-11) 6 (3-11)
Total, n (%) 32 (60) 16 (30) 5 (9.4)
note: GI=Gastrointestinal, ICH=Intracranial Hemorrhage, IQR=Inter-Quartile Range
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of a fatal pericardial (after dabigatran resumption) and two minor bleedings (before 
anticoagulation resumption), all occurring within 10 days and at the same anatomical 
location of the index presentation.
deaths
During the 90-day follow up, 17 patients died (19%); 10 (11%) within five days. Of these 
17 patients, 12 had presented with bleeding (six intracranial) and five underwent urgent 
intervention. The Kaplan-Meier curve of cumulative survival is shown in figure 2. Causes 
of death within five days were: sepsis (three patients), postoperative shock (three pa-
tients; one possibly related to bleeding), intracranial bleeding (two patients), pericardial 
bleeding (one patient) and lung bleeding (one patient). Other causes of death after five 
days were sepsis (three patients), unknown (two patients), intracranial bleeding (one 
patient), pericardial bleeding (one patient) and pulmonary embolism (one patient).
antithrombotic therapy resumption
Overall, antithrombotic therapy was restarted in 60 of 88 patients (68%); in 31 of 35 
patients (89%) requiring intervention after a median of 3 days (IQR 1-5) and in 30 of 
53 patients (57%) presenting with bleeding after a median of 6 days (IQR 3-11). A total 
of 51 patients (58%) restarted dabigatran and nine patients were switched to other 
antithrombotic regimens; five to VKA, three to LMWH (one prophylactic and two thera-
peutic) and one to apixaban.
















Ischemic stroke 1 2 Unknown 65 150 Pericardial
Fatal pulmonary embolism 5 - - 92 110 ICH
Ischemic stroke 21 - 4 73 150 ICH
Pulmonary embolism 41 - 1 79 110 GI
Re-bleeding
GI (minor) 3 - - 73 150 GI
Lung (minor) 6 - 6 85 110 Lung
Pericardial (major) 6 2 - 65 150 Pericardial
Fatal pericardial (major) 9 - - 82 110 Pericardial
note: ICH=Intracranial Hemorrhage, GI=Gastrointestinal
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dISCuSSIon
The main findings of this practice based cohort study were that idarucizumab usage 
was considered inappropriate in 28% of patients, mostly due to interventions that could 
have been delayed and gastrointestinal bleeding complications that might also have re-
sponded to supportive measures alone. For patients presenting with bleeding, two third 
achieved effective hemostasis after idarucizumab administration, which was associated 
with lower mortality risk. In line with the REVERSE-AD study, we observed a 4.2% rate 
of thromboembolic and bleeding events, and a mortality rate of 19% within 90 days (6).
The predefined criteria for appropriateness were based on the recent ISTH guidance 
for DOAC reversal which is in line with international guideline recommendations of the 
European Society of Cardiology (2016) and the American Heart Association (2017) (9-
11). After adjudication, forty percent of interventions could have been delayed for at 
least eight hours and 15% of bleedings were located in the gastrointestinal tract that 
might also have responded to supportive measures alone. Inappropriate usage is likely 
the result of the acute critical care setting in which a prompt decision is required, as 
is illustrated by one patient who incorrectly received idarucizumab while using rivar-
oxaban. In addition, hospital logistics might also have played an important role in the 
decision not to delay interventions, as operating room schedules may not always allow 
awaiting full dabigatran clearance. Moreover, it might have been difficult to foresee the 
time needed to await dabigatran clearance in patients with moderate to severe renal 
impairment. In order to prevent inappropriate idarucizumab usage, clinicians should 
attentively manage dabigatran intake and assess the urgency of the intervention as well 
figure 2. Kaplan Meier 90-day survival curve of 88 patients after idarucizumab administration, stratified 
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as the bleeding severity when deciding upon administration. Ideally, the decision to 
administer idarucizumab should be made by a multidisciplinary team.
Results of laboratory test may guide the decision whether or not to administer idaru-
cizumab, except for patients with life-threatening conditions in whom a rapid decision 
is required. Specific dabigatran tests for accurate estimation of dabigatran plasma con-
centrations, i.e. the diluted thrombin time (dTT) and the ecarin clotting time (ECT), were 
infrequently used in our study, although these tests were available in 10 of 12 included 
hospitals. Applying these tests however requires careful preparation of the specific 
reagents and materials as well as the presence of an experienced laboratory worker to 
perform the procedure and analyses. This probably resulted in the low rate of use in the 
acute setting. The fact that the aPTT test was frequently used to estimate dabigatran 
plasma levels supports this conclusion.
Inappropriate usage has some important drawbacks. Despite an observed non-
procoagulant activity of idarucizumab (5), the attributable thrombotic risk has not yet 
accurately been determined. Inappropriate usage also significantly increases health care 
costs as the average wholesale price package of two idarucizumab 2.5 g/50 mL vials 
is approximately €2600. In addition, there is still insufficient knowledge about the risk 
of hypersensitivity and significant drug interactions associated with idarucizumab (14). 
Hereditary fructose intolerance could, for instance, induce a serious adverse reaction 
due to sorbitol excipients that are processed in the idarucizumab compound (3). Thus, 
inappropriate usage has impact on both patients’ safety as well as healthcare cost.
Our observation of effective hemostasis is similar to those reported in the Andexanet 
Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors (ANNEXA-4) study 
and to Sarode et al. (2013) evaluating the use of prothrombin complex concentrates 
(PCC) in VKA (15, 16). This similar effectiveness indicates that these reversal agents are all 
effective or, alternatively, have minimal or no effect. In the present study, bleeding local-
ization was not related to effectiveness. However, as may be expected, failure to achieve 
effective hemostasis was associated with higher mortality risk. These comprised mostly 
patients with intracranial bleeding who are generally at high risk of poor outcomes (17).
The 90-day thromboembolic (4.2%), bleeding (4.2%) and mortality (19%) rates were 
consistent with those reported by the large RE-VERSE AD trial (6). This clearly reflects the 
similarities between study populations, involving comparable baseline characteristics 
and a similar distribution of bleedings and interventions. The observed 5-day mortality 
rate of 11% underlines the poor prognosis of the patients enrolled with uncontrollable 
bleeding or requiring emergency interventions. Moreover, the most frequent cause of 
death does not seem related to bleeding or thromboembolism, but may be driven by the 
underlying disease. Importantly, it is difficult to analyze the real impact of idarucizumab 
on patient outcome as there can be no control group for ethical reasons. The 2.1% 
30-day thromboembolic rate in our study was lower than those reported in previous 
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studies evaluating prothrombin complex concentrate (PCC) for the reversal of VKA or 
Xa-inhibitors, in which thrombotic rates between 4% and 8% were demonstrated (15, 18, 
19). Although an indirect comparison, this difference might be explained by the fact that 
we observed a large part of patients requiring interventions, in which anticoagulation 
therapy was more rapidly and frequently resumed, whereas these studies only included 
patients with bleeding (15, 18, 19). The timing of resumption after a bleeding episode 
is clearly more difficult. A recent ESC consensus recommends resumption after major 
bleeding as soon as the thrombotic risks outweigh the re-bleeding risks, in most cases 
within one week (20). Although this was consistent with an observed median duration 
of six days in our study, all thrombotic and (re-) bleeding events occurred in patients 
presenting with bleeding. Results of randomized trials evaluating optimal anticoagula-
tion resumption after severe bleeding are eagerly awaited.
To our knowledge, this is the largest practice-based cohort of consecutive patients 
treated with idarucizumab. No exclusion criteria were applied, which makes the study 
generalizable to the population treated with idarucizumab. Also, standardized ISTH 
criteria were used for the evaluation of appropriate usage (11). Each case was indepen-
dently adjudicated. Our data provide further insight into clinical practice in different 
situations in which idarucizumab currently is used and its role for the management of 
urgent dabigatran reversal.
The most important limitation of our study was the retrospective design. Inherently, 
we might not have accurately reconstructed the line of clinical reasoning in the acute 
setting. To deal with this issue, medical reports were meticulously scrutinized before the 
independent adjudication process occurred. In addition, the hemostatic effectiveness 
could not be determined in 10% of patients because required ISTH criteria for this as-
sessment could not completely be retrieved from the medical reports.
In conclusion, idarucizumab usage was considered inappropriate in 28% of patients, 
mostly due to interventions that could have been delayed and gastrointestinal bleeding 
complications that might have responded to supportive measures alone. Of note, the 
criteria applied to judge appropriateness have not been tested in clinical trials and may 
not fully reflect daily clinical care on crowded emergency rooms. Two third of bleeding 
patients achieved effective hemostasis which was associated with a lower mortality risk 
compared to patients with ineffective hemostasis. Clinical outcome of patients treated 
with idarucizumab was similar to those observed in the RE-VERSE AD trial(6), comprising 
(fatal) re-bleeds and thromboembolism, and a high mortality rate.
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Although dabigatran has a favourable risk-benefit profile compared to vitamin K an-
tagonist therapy for venous thromboembolism and non-valvular atrial fibrillation, major 
bleeding events - including gastrointestinal (GI) bleeding - may occur. Therefore, our aim 
was to provide insights on the efficacy and safety of idarucizumab for urgent dabigatran 
reversal in patients with major GI bleeding.
Methods
Patients with uncontrollable GI bleeding were enrolled from June 2014 through July 
2016 in RE-VERSE AD™, a prospective, multi-centre, open-label study of idarucizumab 
and were followed for 90 days for primary and secondary outcomes. Patients were to 
receive a 5g dose of intravenous idarucizumab, administered as two bolus infusions of 
2.5g no more than 15 minutes apart.
The primary endpoint was the maximum reversal of dabigatran anticoagulation within 
four hours after administration of idarucizumab as measured by the dabigatran-specific 
assays diluted thrombin time (dTT) and ecarin clotting time (ECT). Further endpoints in-
cluded investigator-reported bleeding cessation within the first 24 hours, and incidence 
of re-bleeding, thromboembolic events and/or mortality.
Result
GI bleeding occurred in 137 patients enrolled in REVERSE-AD, of which 48 (35.0%) were 
upper GI tract in origin, 43 (31.4%) were lower, and 46 (33.6%) were either both or un-
known. Complete reversal of dabigatran was observed in 118 of 121 (97.5%) patients 
with an elevated dTT at presentation and 95 of 131 (72.5%) with an elevated ECT, and 
was similar for upper and lower GI bleeding. Bleeding cessation within 24 hours was 
reported in 92 of 134 evaluable patients (68.7%) after a median duration of 2.4 hours 
(IQR 2.0-3.9). During the 90-day follow up, six patients (4.4%) had a post-reversal throm-
boembolic event and 20 patients (14.6%) died.
Conclusions
Idarucizumab showed a rapid and complete reversal of dabigatran activity in nearly all 
patients presenting with GI bleeding, facilitating emergency patient care without the 
additional presence of anticoagulation.
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InTRoduCTIon
Dabigatran etexilate (Pradaxa®) is a direct thrombin inhibitor that has a favorable risk-
benefit profile compared to vitamin K antagonists (VKA) for the prevention of ischemic 
stroke in patients with non-valvular atrial fibrillation and treatment of patients with 
venous thromboembolism (1, 2). Even so, as with all anticoagulants, dabigatran still 
confers a risk of gastrointestinal (GI) bleeding that in rare cases can lead to hemody-
namic instability and result in high risk for morbidity and mortality (3). In patients with 
non-valvular atrial fibrillation, the 150 mg BID dose of dabigatran was associated with an 
increased risk of GI bleeding and the 110 mg BID dose was comparable to VKA (1). Thus, 
an agent that can rapidly counteract the anticoagulant effect of dabigatran in these 
patients would be a valuable tool in severe bleeding management.
Idarucizumab (Praxbind®) is a humanized monoclonal antibody fragment that binds 
dabigatran with high affinity, neutralizing its ability to inhibit thrombin (4, 5). In the 
RE-VERSE AD study, idarucizumab provided rapid, effective, safe, and durable reversal 
of dabigatran activity in the presence of uncontrollable hemorrhage or the need for 
urgent surgery (6). Prior to the availability of idarucizumab, treatment and prevention 
of uncontrollable bleeding in dabigatran-treated patients involved supportive care and 
non-specific blood products (1, 7, 8). Experience with the use of coagulation factors such 
as prothrombin complex concentrate (PCC) to antagonize dabigatran activity is limited 
and its effectiveness has never been studied in clinical trials (9).
In the large RE-VERSE AD study, GI bleeding accounted for 45.5% of all qualifying 
bleeding events, which was the most frequent organ system location (6). The purpose 
of the present analysis is to provide insights from RE-VERSE AD regarding the extent of 
dabigatran reversal, the frequency of full bleeding cessation within the first 24 hours, 
and occurrence of both thromboembolic events and mortality over a 90-day follow up 
period in patients reversed for uncontrollable GI bleeding.
MeThodS
Study design and population
The RE-VERSE AD study was a prospective, multicenter, open-label cohort evaluation of 
the efficacy and safety of idarucizumab in the reversal of dabigatran-related anticoagu-
lation. The design and rationale for REVERSE-AD as well as its main results have been 
published previously (6, 10). Briefly, two dabigatran-treated patient groups were evalu-
ated: Group A comprised patients who had uncontrollable bleeding that was judged 
by the clinician to warrant acute reversal and Group B consisted of patients who were 
about to undergo an intervention that could not be delayed for at least 8 hours. Every 
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patient received intravenous idarucizumab, administered as two 50ml bolus infusions, 
each containing 2.5g idarucizumab, no more than 15 minutes apart. Patients were 
classified by the site investigator as having upper or lower GI tract bleeding, defined 
respectively as bleeding that was presumed to originate from a source proximal or distal 
to the ligament of Treitz respectively, as diagnosed clinically, by imaging and/or by en-
doscopic examination as guided by clinical presentation (11). All patients provided writ-
ten informed consent. The study protocol was approved by all the relevant institutional 
review boards. The data, analytic methods, and study materials will be made available 
on request to other researchers for purposes of reproducing the results or replicating 
the procedure.
Study endpoints and follow-up procedures
The primary endpoint of RE-VERSE AD was the maximum reversal of dabigatran’s antico-
agulant activity as measured by the diluted thrombin time (dTT) or ecarin clotting time 
(ECT) within 4 hours after the end of the second infusion of idarucizumab. Complete 
reversal was achieved if assay results were at or below the upper limit of normal (ULN) 
for at least one of five time points during the first 4 hours post-idarucizumab infusion. 
Both the dTT and ECT have previously been shown to correlate to actual dabigatran 
levels across a wide concentration range (5). The activated partial thrombin time (aPTT, 
both in local and reference laboratories) was also evaluated as an endpoint in RE-VERSE 
AD. Since both ECT and aPTT are also subject to greater test variability, the main focus of 
the present study was the change in dTT. Reversal of ECT and aPTT values was reported 
in the supplement. The maximum reversal of dabigatran was calculated as follows: 
percentage reversal = (predose test result [in seconds] – minimum postdose test result 
[in seconds]) / (predose test result [in seconds] – upper limit of the normal range [in sec-
onds]) × 100%. The ULN of the dTT in the reference laboratory was 36 seconds (10). The 
minimum postdose test result is the lowest value from the five measurements within 
four hours. Patients without elevated dTT values were treated with idarucizumab based 
on clinical necessity and were included in all safety analyses, but were excluded from 
our primary analysis.
Further endpoints included: 1) time to bleeding cessation, as assessed by the treating 
physician and defined by stabilization of pulse, blood pressure and/or of hemoglobin 
values or, if the site was endoscopically evaluable, visible determination, 2) post-reversal 
re-bleeding and thrombotic events occurring within 90 days of reversal; and 3) death. 
The extent of bleeding and hemodynamic stability were assessed by the site investi-
gator between 10 and 30 minutes and at 1, 2, 4, 12, and 24 hours after idarucizumab 
administration, or when considered clinically appropriate. All bleeding events were 
censored at a maximum duration of 24 +/- 1 hours. Patients were enrolled based on clini-
cal presentation of uncontrolled bleeding that in the opinion of the treating clinician 
Idarucizumab in patients with GI bleeding 117
required immediate reversal of anticoagulation. The severity of bleeding was classified 
post-hoc using the International Society on Thrombosis and Haemostasis (ISTH) criteria 
(12). Patients were followed from the time of idarucizumab infusion up to 90 days after 
the infusion. The occurrence of, any suspected thrombotic events and deaths were 
recorded and adjudicated by an independent committee. Two patients died outside the 
protocol-specified 90 day follow up, and are not included in further analyses.
Statistics
Data were analyzed using descriptive statistics expressed as either the mean (standard 
deviation [SD]) or median (interquartile range [IQR]). For categorical variables, frequen-
cies (n) and percentages (%) were used. The primary endpoint of the maximum dabi-
gatran reversal within 4 hours of idarucizumab administration was only calculated for 
patients in whom pre-treatment values exceeded the upper limit of the normal range in 
the central laboratory (6). All analyses were performed using the statistical software SAS 
version 9.4 (SAS Institute, Cary, N.C).
ReSuLTS
Patient characteristics
The GI tract was the site of qualifying hemorrhage in 137 of 301 (45.5%) of bleeding 
patients enrolled in Group A of the REVERSE-AD cohort, representing the commonest 
organ source of hemorrhage.(6) Of the 137 patients, 43 (31.4%) presented with lower 
and 48 (35.0%) for upper GI bleeding; four patients (2.9%) had both upper and lower GI 
bleeding and in 42 patients (30.7%) the bleeding site remained unidentified. Patients’ 
demographics did not differ by location of the GI bleeding. The mean age was 78 years 
(SD 10) and 75 patients (54.7%) were male. Ninety-one patients (66.4%) were on the 110 
mg BID dose. Many patients had additional comorbidities, including 114 (83.2%) with 
hypertension, 68 (49.6%) with chronic heart failure and 39 (28.5%) with prior stroke or 
TIA (Table 1). Proton pump inhibitors were used at presentation in 38 patients (27.7%) 
and 20 patients (14.6%) were treated with antiplatelet therapy alongside dabigatran. The 
median hemoglobin level at baseline was 8.1 g/dL (IQR 6.7-10.1). The patient-reported 
last dabigatran intake was at a median of 13 hours (IQR 8-20) prior to idarucizumab 
administration. A total of 121 (88.3%) patients had elevated dTT levels at enrollment 
with a median of 58 seconds (IQR 44-86). ISTH bleeding was classified as minor in 16% of 
patients with GI bleeds, however, dabigatran levels, time since the last dabigatran dose 
and baseline dTT were similar regardless of whether the patients with minor bleeds 
were included in the cohort or not.
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Table 1. Baseline characteristics of 137 patients enrolled with gastrointestinal (GI) bleeding. Data in pa-
tients with both upper and lower bleeding are presented as range instead of IQR due to small numbers.
Clinical characteristic












Age (years), mean ± SD 80 ± 7 77 ± 13 79 ± 9 78 ± 7 78 ± 10
Male sex, n (%) 22 (51.1) 28 (58.3) 24 (57.1) 1 (25.0) 75 (54.7)
BMI (kg/m2)#, mean ± (SD) 27 ± 4.9 27 ± 6.7 29 ± 11.6 27 ± 4.3 28 ± 7.9
Comorbidities, n (%)
Hypertension 36 (83.7) 37 (77.1) 38 (90.5) 3 (75.0) 114 (83.2)
CHF 19 (44.2) 27 (56.3) 21 (50.0) 1 (25.0) 68 (49.6)
Diabetes 10 (23.3) 18 (37.5) 14 (33.3) 2 (50.0) 44 (32.1)
Prior ischemic stroke/TIA 14 (32.6) 11 (22.9) 13 (31.0) 1 (25.0) 39 (28.5)
Prior major bleeding 3 (7.0) 6 (12.5) 3 (7.1) 0 12 (8.8)
Active cancer 2 (4.7) 7 (14.6) 1 (2.4) 0 10 (7.3)
Creatinine clearance (ml/min)°, 
median (IQR)
49 (37-63) 49 (29-59) 39 (31-59) 37 (21-65) 46 (31-60)
Hemoglobin level (g/dL)^, 
median (IQR)
9.5 (7.7-10.4) 7.6 (6.0-10.1) 7.8 (6.7-9.2) 8.1 (4.7-10.5) 8.1 (6.7-10.1)
Bleeding severity (ISTH criteria), n (%)
Minor 9 (20.9) 8 (16.7) 4 (9.5) 1 (25.0) 22 (16.1)
Major 28 (65.1) 27 (56.3) 26 (61.9) 1 (25.0) 82 (59.9)
Life-threatening 5 (11.6) 12 (25.0) 11 (26.2) 2 (50.0) 30 (21.9)
Not assessable 1 (2.3) 1 (2.1) 1 (2.4) 0 3 (2.2)
Dabigatran dose, n (%)
150 mg BID 6 (14.0) 14 (29.2) 16 (38.1) 1 (25.0) 37 (27.0)
110 mg BID 35 (81.4) 30 (62.5) 23 (54.8) 3 (75.0) 91 (66.4)
75 mg BID 2 (4.7) 3 (6.3) 3 (7.1) 0 8 (5.8)
Missing 0 1 (2.1) 0 0 1 (0.7)
Time since last dabigatran dose 
(hours)§, median (IQR)
14 (9-24) 13 (8-17) 13 (7-30) 5 (4-10) 13 (8-20)
Elevated dTT at baseline*, n (%) 41 (95.3) 38 (79.2) 38 (90.5) 4 (100) 121 (88.3)
Baseline dTT (seconds)*, median 
(IQR)
56 (46-70) 55 (42-86) 65 (42-90) 72 (58-112) 58 (44-86)
Concomitant medication use, n (%)
Antiplatelet 6 (14.0) 6 (12.5) 7 (16.7) 1 (25.0) 20 (14.6)
NSAID 0 0 1 (2.4) 0 1 (0.7)
Proton Pump Inhibitor 13 (30.2) 12 (25.0) 12 (28.6) 1 (25.0) 38 (27.7)
note: #7 patients with missing BMI; °3 with missing creatinine clearance; ^2 with missing hemoglobin level; 
§1 with missing time since last dabigatran dose; *3 with missing dTT at baseline.
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GI tract pathology was also recorded at the time of patient enrollment into the study, 
although this was not mandatory and may represent under-reporting of actual pathol-
ogy (Supplement Table 1). Gastric and duodenal ulcers were common in those with 
upper GI bleeding (25.0%), whereas polyps and diverticular disease were identified 
frequently in patients with lower GI bleeding (9.3% and 16.3% respectively). Newly di-
agnosed luminal GI cancer was reported in at least 2 patients in source documentation, 
one with a GI stromal tumour and one with pancreatic carcinoma involving the stomach. 
This information reporting was not mandatory, and may represent under-reporting; it 
was also not captured in the clinical database.
dabigatran reversal
The median time between the start of administering the first vial of idarucizumab to 
the end of the last vial was 19 minutes (14-25 minutes) in patients with GI bleeding. 
Complete anticoagulation reversal was observed within 10-30 minutes in 118 of the 
121 patients (97.5%) with elevated dTT values at baseline and was similar for all sites of 
GI bleeding (figure 1). The three patients (2.5%) without complete initial reversal had 
three to seven fold increased ULN dTT values but still had a reversal effect of at least 
50%. This reversal persisted for at least four hours in 110 of 121 patients (90.9%) and up 
to 24 hours in 71 of 121 patients (58.7%). Extent of reversal using the ECT and (central 
laboratory) aPTT assays were comparable to reversal with dTT (Supplement figure 1 
and 2).
A re-elevation of dTT above ULN occurred in 25 patients (20.7%) within twelve hours 
and in 50 patients (41.3%) within 24 hours. In 10 of these 50 patients (20.0%) re-bleeding 
was reported within 48 hours after idarucizumab administration. These 10 re-bleeding 
patients had higher baseline dTT levels (median 115.5, IQR 79-134, versus 87 seconds, 
IQR 65-101) as well as higher dTT re-elevation levels at 24 hours (median 66, IQR 54-89, 
versus 41 seconds, IQR 38-48) compared to the 40 patients with re-elevation but no re-
bleeding. Three of these patients also received a second 5g dose of idarucizumab after a 
re-bleeding episode (Supplement figure 3). These patients had a creatinine clearance 
at enrollment of 26, 43 and 29 mL/min and dTT at baseline of 133, 79 and 78 seconds. A 
second dose of idarucizumab was administered between 24 and 48 hours after the first 
dose, the dTT prior to the second dose was 74, 70 and 55 seconds. Cessation of bleeding 
occurred in all three patients within an hour and reducing the dTT reversed to below 




In patients with lower GI bleeding, 76.2% were assessable within 24 (+1) hours, with a 
time of 2.1 hours (1.3-7.9) to bleeding cessation (Table 2). Bleeding cessation occurred 
in 9.5% of patients at time points >25 hours, and could not be confirmed in 14.3% of 
patients. In the upper GI location, 82.6% were assessable within 24 (+1) hours, with a 
figure 1. Reversal of diluted thrombin time (dTT) after administration of idarucizumab (rectangular box 
in each graph) in patients with lower or upper gastrointestinal (GI) bleeds or in those with unknown loca-
tions or with both upper and lower bleeding. Data points represent individual patients. ULN: upper limit of 
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median time of 2.7 (1.5-9.6) hours, 4.3% of patients stopped bleeding >25 hours and 
13.0% were not assessable. In patients with an unknown location of GI bleed, 52.4% 
were assessable within 24 (+1) hours, with a median of 3.2 (2.0-6.5) hours, 14.3% stopped 
bleeding at times >25 hours and 33.3% were not confirmed. In patients with more than 
one location, bleeding cessation occurred within 24 (+1) hours in 100% of patients after 
6.4 (0.8-16.0) hours.
blood product management
A total of 117 patients (85.4%) in this cohort also received blood products; 113 (82.5%) 
received packed red blood cell transfusions and 6 (4.4%) received PCCs, 2 (1.5%) acti-
vated PCCs and 1 recombinant activated Factor VII (0.7%; Table 3). Administration of 
these procoagulant agents had no effect on dabigatran reversal by idarucizumab as 
demonstrated by dTT, ECT and aPTT (data not shown).
Thromboembolic events and anticoagulation resumption
A total of six patients (4.4%) experienced seven thromboembolic events during the 
90-day follow up period, of which four occurred within 30 days (2.9%; Table 2). Five 
of these events in four patients occurred in the absence of anticoagulation: one myo-
cardial infarction, one day after first idarucizumab dose, two deep vein thromboses 
(one with concurrent pulmonary embolism), occurring at two days, and one ischemic 
stroke, occurring at 35 days post-idarucizumab. Two ischemic strokes occurred 19 and 
74 days post-idarucizumab while anticoagulant therapy was restarted (Table 4). Overall, 
Table 2. Time to bleeding cessation, number of thrombotic events and mortality in 137 patients with 
gastrointestinal (GI) bleeding after receiving idarucizumab. Patients could not be evaluated if bleeding 
stopped prior to idarucizumab (n=1) or there was no post-baseline bleeding assessment possible (n=2).












Evaluated patients 42 46 42 4 134
Time to cessation (hrs), median (IQR) 2.0 (1.3-6.4) 2.7 (1.5-8.0) 2.7 (1.9-6.1) 6.4 (0.8-16.0) 2.4 (1.5-6.4)
Patients with Thrombotic events, n (%)
0-5 days 0 2 (4.2) 1 (2.4) 0 3 (2.2)
0-30 days 0 2 (4.2) 2 (4.8) 0 4 (2.9)
0-90 days 0 3 (6.3) 3 (7.1) 0 6 (4.4)
Mortality, n (%)
0-5 days 1 (2.3) 1 (2.1) 3 (7.1) 0 5 (3.6)
0-30 days 3 (7.0) 6 (12.5) 6 (14.3) 0 15 (10.9)
0-90 days 5 (11.6) 7 (14.6) 8 (19.0) 0 20 (14.6)
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Table 4. Thrombotic events occurring in patients after receiving idarucizumab for management of gastro-
intestinal (GI) bleeding associated with dabigatran.
Thrombotic event
anatomic 
















Upper 1 - 6.4 Albumin
Deep venous 
thrombosis
Upper 2 - 13.7 PRBCs
Pulmonary 
embolism + deep 
venous thrombosis
Unknown 2 2 23.5 PRBCs, TxA, FFP
Fatal Ischemic stroke Unknown 19 5.3 - PRBCs, FFP, Platelets
Ischemic stroke Upper 35 35.2 - PRBCs
Fatal Ischemic stroke Unknown 74 48.9 55.0 Whole blood
note: PRBCs=Packed Red Blood Cells, TxA=Tranexamic Acid, FFP=Fresh Frozen Plasma.
Table 3. The number of patients presenting with gastrointestinal (GI) bleeding who received hemostatic 
agents both prior to and post idarucizumab treatment. All data is presented as n (%).
Patients receiving blood 
products











Overall 36 (83.7) 41 (85.4) 37 (88.1) 3 (75.0) 117 (85.4)
blood components
Packed red blood cells 33 (76.7) 41 (85.4) 36 (85.7) 3 (75.0) 113 (82.5)
Fresh Frozen Plasma 10 (23.3) 14 (29.2) 10 (23.8) 1 (25.0) 35 (25.5)
Platelets 1 (2.3) 2 (4.2) 5 (11.9) 0 8 (5.8)
Cryoprecipitate 1 (2.3) 1 (2.1) 1 (2.4) 0 3 (2.2)
Whole blood 1 (2.3) 0 1 (2.4) 0 2 (1.5)
Coagulation factor Concentrates
3 or 4-factor prothrombin 
complex concentrate (PCC)
3 (7.0) 2 (4.2) 1 (2.4) 0 6 (4.4)
Recombinant activated Factor 
VII
0 0 1 (2.4) 0 1 (0.7)
Activated prothrombin complex 
concentrate (aPCC)
1 (2.3) 0 1 (2.4) 0 2 (1.5)
Volume expanders, prohemostatic agents
Volume expanders 12 (27.9) 10 (20.8) 1 (2.4) 0 23 (16.8)
Tranexamic acid 10 (23.3) 5 (10.4) 10 (23.8) 0 25 (18.2)
Other 0 0 1 (2.4) 0 1 (0.7)
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48 patients (35.0%) received parenteral anticoagulation during hospitalization and 91 
patients (66.4%) restarted some form of oral anticoagulant therapy after a median of 16 
days (IQR 7-34; Supplement Table 2). In 31 patients (22.6%) dabigatran was resumed 
after a median of 16 days (IQR 6-38). Overall, patients were discharged from hospital 
after a median of seven days (IQR 4-12).
Mortality
The 30-day and 90-day mortality was 10.9% (15 patients) and 14.6% (20 patients) 
respectively (Table 3). The median time of death was 18 days (IQR 6-35) post idaruci-
zumab. Causes of death included cardiac failure (four patients), respiratory failure/infec-
tion (three patients), myocardial infarction (three patients), hemorrhage (two patients) 
and, kidney failure, sepsis, electrolyte imbalance, inanition, disseminated intravascular 
coagulation, ischemic stroke, Parkinson’s disease and sudden death (one patient each).
dISCuSSIon
The main finding of this post-hoc analysis of the REVERSE-AD study is that idarucizumab 
showed a rapid and complete reversal of dabigatran activity in 97.5% of patients pre-
senting with GI bleeding who had an elevated diluted thrombin time (dTT) regardless 
of the GI bleeding location.
This highly efficacious reversal is consistent with the published results of the entire 
REVERSE-AD study, which included patients with bleeding into other organs and in non-
bleeding patients requiring urgent interventions while anticoagulated with dabigatran 
(6). Overall, reversal was achieved rapidly and persisted up to 24 hours in the majority 
of patients after one dose of idarucizumab. The rapid and immediate decrease of dTT 
values demonstrates that reversal of dabigatran is directly related to the administration 
of idarucizumab and is consistent with its mechanism of action and previous results in 
healthy volunteers (4, 13). After 24 hours, 50 patients (41.3%) had a re-elevation of dTT 
values above the ULN. Re-elevation of dabigatran is possibly due to the redistribution of 
unbound dabigatran from the peripheral tissues to the intravascular compartment over 
time, since idarucizumab is rapidly cleared (~95% of the dose is cleared 4 hours after 
administration) (6). Re-elevation of the dTT was associated with re-bleeding in 10 of 50 
patients (20%). In general, patients with re-bleeding had a high baseline dTT and higher 
re-elevated dTT levels at 24 hours. Measurement of anticoagulation in hospitalized 
patients after a GI bleed may be important for further clinical assessment. If re-bleeding 
occurs and clotting assays are elevated, then a second dose of idarucizumab may be 
warranted (14). However, if re-bleeding occurs but clotting assays are not elevated, then 
re-bleeding is likely anticoagulant independent and should be addressed with bleeding 
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management procedures. Clinical variables such as blood pressure, effect of the initial 
intervention and thrombocyte count may also be important contributors to re-bleeding.
A second dose of idarucizumab was administered to three patients with re-bleeding, 
in whom the dTT reversed to below ULN and re-bleeding stopped promptly within an 
hour. This illustrates that in rare cases a second dose was indicated to stop the bleeding, 
which was well tolerated by patients.
The present study provides important information that dabigatran activity was com-
pletely reversed in patients presenting with uncontrollable GI bleeding. The frequency 
of GI bleeding from upper or lower GI tract locations in dabigatran-treated patients was 
comparable and consistent with previous observations (15, 16). Also, in accordance with 
earlier findings, the frequency of upper GI bleeding was primarily due to ulceration, 
whereas lower GI bleeding was frequently associated with diverticulosis and polyps (17, 
18). Interestingly, the location of GI bleeding remained unidentified in 31% of the pa-
tients. This could be due to a bleeding source within the small intestine at a site beyond 
the reach of traditional endoscopy or, to delayed or absent diagnostic evaluation.
Overall, 82.5% of the patients received red blood cell transfusions, which was higher 
than reported by other studies (19, 20). A study performed by Pannach et al. (2017), 
including all major GI bleeding events documented in a prospective non-vitamin K 
dependent oral anticoagulant (NOAC) registry, found 44% red blood cell transfusions 
in 143 patients using NOACs (19). In addition, an observational study performed by 
Yan Xu et al. (2017) found this rate to be 52% in 460 NOAC-related bleeding events, 
which mostly were located in the GI tract (20), who had potentially more serious events 
than in other studies (12). In the study by Yan Xu et al. (2017) PCC and rFVIIa were more 
frequently used than in our study, possibly because idarucizumab was not available in 
their study (20). In all cases of major GI bleeding, there is variation among clinicians in 
identifying and acting upon thresholds for transfusion therapy.
Twenty of 137 patients with an index event of GI bleeding died during the 90-day 
follow up. This underlines the poor prognosis of the critically ill patients in the pres-
ent study, of whom many presented with hemodynamic instability and suffered from 
co-morbidities, despite normalization of coagulation. In addition, the long follow-up of 
these elderly patients in this study precludes direct comparisons to other studies, where 
follow-up duration is often shorter. The in-hospital mortality in a study by Pannach et 
al. (2017) was 1.6% in NOAC-treated patients and 5.6% in VKA-treated patients (mean 
hospital stay, 6.9 and 12.6 days, respectively) (19). Though in-hospital mortality was not 
recorded in our study, the five day mortality was 3.6%, consistent with these results. Pan-
nach et al. (2017) also included patients with controllable GI bleeding, again reflecting 
the more severely ill patients enrolled in the current study and potentially explaining the 
higher mortality rate.
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The incidence of thromboembolic events after 30 and 90 days was 2.9% and 4.4% re-
spectively, which is comparable with a pooled 2.3% (95%CI 0.5-5.4) incidence reported 
in patients requiring urgent VKA reversal by PCCs in high quality studies with varying 
follow up durations (21). Importantly, nearly all thromboembolic events occurred in 
patients in whom oral anticoagulation had not been restarted. One third of the patients 
did not resume any form of anticoagulant therapy, consistent with findings of Pannach et 
al. (2017) (19). There is limited evidence to support the decision and timing of resuming 
anticoagulation after GI bleeding. Current American College of Gastroenterology guide-
lines do not discuss the resumption of oral anticoagulation after GI bleeding, whereas 
current European Society of Cardiology guidelines suggest that an oral anticoagulant 
should be restarted as soon as the thrombotic risk outweighs the bleeding risk, mostly 
within one week (22, 23). Available scant evidence from VKA experience suggests that 
the optimal timing to restart oral anticoagulation after a GI bleeding is around 7 to 15 
days (24). This is in line with our study in which oral anticoagulation was restarted after 
a median time of 16 days from the initial GI bleeding event.
Strengths and limitations
This is the first analysis focusing on idarucizumab use in patients with GI bleeding. Be-
cause of the pragmatic design of this study, it reflects usual acute clinical care. These data 
may provide further insights to practicing physicians about the role of idarucizumab in 
the management of dabigatran-related major GI bleeding.
This study had several limitations. First, a control group is lacking because ethical 
aspects prohibited the inclusion of a placebo control group in very sick patients with no 
alternative targeted reversal treatment available (6). Second, the study protocol did not 
require collection of specific details of diagnostic and interventional endoscopic proce-
dures. Third, details of cessation of bleeding could not always accurately be assessed in 
non-visible GI bleeding. Nonetheless, the clinical impact of bleeding events was always 
assessed by the attending physician.
In conclusion, idarucizumab showed a rapid and complete reversal of dabigatran 
activity in nearly all patients presenting with GI bleeding, regardless of the localisation, 
and can be safely administered in conjunction with hemostatic agents. Our findings 
provide relevant further insights to practising physicians on the role of idarucizumab in 
the management of dabigatran-related major GI bleeding events.
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This thesis aimed to evaluate and improve therapeutic anticoagulation strategies in 
patients presenting with venous thromboembolism (VTE) and to prevent arterial throm-
bosis after heart valve surgery. In addition, this thesis aimed to establish optimal major 
bleeding management with idarucizumab for urgent dabigatran reversal. Chapter 1 
comprises a general introduction and overview of the presented studies.
Part I: Venous thromboembolism
Chapter 2 describes the results of a systematic review and meta-analysis on the fatal 
recurrent VTE risk after anticoagulation discontinuation in patients initially presenting 
with unprovoked VTE. A total of 8,914 patients were included in 24 high-quality studies. 
We observed a pooled fatal recurrent VTE fatality rate of 0.13 (95%CI 0.036-0.25) per 
100 patient-years with a case-fatality rate of 2.0% (95%CI 0.69-3.8) in studies with high 
heterogeneity. These findings provide a key missing piece of information on whether 
or not to prolong anticoagulation treatment in patients with unprovoked VTE beyond 
the first 3 months. Current guideline recommendations on the duration of treatment of 
unprovoked VTE would be strengthened if future observational studies show that long-
term anticoagulation treatment with direct oral anticoagulants (DOACs) is associated 
with a rate of fatal bleeding lower than 0.25% per year, representing the upper limit of 
the 95% confidence interval of the pooled incident rate of fatal recurrent VTE.
The two following chapters address the adherence of daily low-molecular-weight 
heparin (LMWH) injections in patients with cancer-associated VTE. In chapter 3, we 
evaluated adherence to LMWH therapy during a period of 180 days in 372 patients 
with cancer-associated VTE. This study demonstrated that one out of five patients with 
cancer-associated VTE discontinued LMWH treatment during six months, mostly due 
to unacceptable pain at the injection site. Although this rate may be considered an 
acceptable trade-off against the reported higher risk of recurrent VTE associated with 
vitamin K antagonists (VKA), this finding provides relevant background information 
to current clinical trials investigating the efficacy and safety direct oral anticoagulants 
(DOACs) compared to LMWH. The oral administration of DOACs might be more practical 
and patient-friendly than daily subcutaneous LMWH injections. Furthermore, different 
LMWH compounds might also influence adherence rates. Chapter 4 revealed that 
enoxaparin treatment was associated with a higher risk of discontinuation because of 
side effects compared to nadroparin (hazard ratio 2.8, 95%CI 1.06-7.2). Although further 
investigation is needed, these findings are relevant for choice of LMWH when treating 
cancer-associated VTE. DOAC treatment might be an attractive alternative when DOACs 
are proven non-inferior to LMWH.
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Part II: arterial thrombotic complications after heart valve surgery
After heart valve surgery, patients are at risk of developing systemic arterial thrombo-
embolism. After both bioprosthetic aortic valve implantation and mitral valve repair, 
the most appropriate antithrombotic therapy is still a subject of controversy. In Chapter 
5, we aimed to evaluate the rate of thromboembolic and bleeding complications in 
patients with either acenocoumarol or aspirin therapy after bioprosthetic aortic valve 
implantation, occurring within one year postoperatively. In this multicenter retrospec-
tive study of 402 patients in three Dutch hospitals, acenocoumarol was associated 
with more bleeding episodes (risk ratio: 8.41, 95%CI 3.58–19.79) and a similar amount 
of thromboembolic events (risk ratio: 1.2, 95%CI 0.47–3.02) compared with aspirin. 
This study indicates that aspirin should be favored over acenocoumarol as preferred 
antithrombotic regimen during the first postoperative year. Similarly, the purpose of 
chapter 6 was to compare the rate of thromboembolic and bleeding complications 
in patients with either vitamin K antagonist (VKA) or aspirin therapy after mitral valve 
repair. Among 469 patients, no differences were seen in the 3-month cumulative inci-
dence of the combined end point of thromboembolic and bleeding events between 
aspirin and VKA (hazard ratio: 1.6, 95%CI 0.83-3.1). Moreover, no significant differences 
were observed in thromboembolic rates (hazard ratio: 0.82, 95%CI 0.16-4.2) as well as in 
major bleeding rates (hazard ratio: 1.89, 95%CI 0.90-3.9). These findings suggests that 
the choice of antithrombotic treatment after mitral valve repair should be individual-
ized based on patient-specific considerations, such as risk factors for atrial fibrillation, 
compliance with treatment and frailty.
Part III: Idarucizumab as antidote of dabigatran
Recently, specific reversal agent idarucizumab (Praxbind®) has been recommended for 
urgent dabigatran reversal in patients with uncontrolled or life-threatening bleeding 
or undergoing an emergency procedure. In chapter 7, we assessed appropriate usage 
of idarucizumab in 88 patients which was judged inappropriate in 25 patients (28%). 
Despite the fact that idarucizumab might optimize urgent management, insufficient 
knowledge is available about the risk of hypersensitivity and significant drug interac-
tions. Moreover, inappropriate has a negative impact on the healthcare costs. For 
patients presenting with bleeding, two third achieved effective hemostasis after idaru-
cizumab administration. This proportion was similar to that reported in previous studies 
evaluating the efficacy of other reversal agents. In line with the large REVERSE-AD trial, 
we observed a 4.2% rate of thromboembolic and bleeding events, with a mortality rate 
of 19% within 90 days. This high mortality rate underlines the poor prognosis of the 
patients enrolled with uncontrollable bleeding or requiring emergency interventions. 
Chapter 8 was aimed to provide insights on the efficacy and safety of idarucizumab for 
urgent dabigatran reversal in patients with major gastrointestinal (GI) bleeding. The GI 
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tract was the site of qualifying hemorrhage in 137 of 301 (45.5%) of bleeding patients 
enrolled in Group A of the original REVERSE-AD trial, representing the commonest source 
of hemorrhage. Idarucizumab was shown to rapidly and completely reverse dabigatran 
activity in 98% of patients presenting with GI bleeding who had an elevated diluted 
thrombin time (dTT) regardless of the GI bleeding location. This study confirmed that 
Idarucizumab is effective for reversal of dabigatran anticoagulation in patients present-
ing with a major GI bleeding event.
future perspectives
In the near future, direct oral anticoagulants (DOACs) might not only play an important 
role in venous thrombosis, but also in preventing arterial thrombosis in patients with 
stable cardiovascular disease. Currently, antiplatelet therapy is widely used because 
anticoagulation with vitamin K antagonists (VKAs) - alone or in combination with an-
tiplatelet therapy - was associated with a higher risk of bleeding, including intracranial 
hemorrhage. A recent study evaluating the efficacy and safety of DOACs in patients 
with cardiovascular disease reported a lower rate of arterial thrombotic complications 
of the combination of very low-dose rivaroxaban and aspirin as compared with aspirin 
monotherapy (1). However, further investigation is evidently needed. Other antiplatelet 
agents - particularly dual antiplatelet therapy - should have been involved in the study 
since this combination also was shown to adequately prevent thrombotic complications 
in this patient category. It would be of great interest to compare the combination of 
rivaroxaban and aspirin versus P2Y12 inhibitor (e.g. ticagrelor) monotherapy and the 
combination of a P2Y12 inhibitor and aspirin. Such a study will probably downsize the 
promising results of DOACs in preventing arterial thrombosis.
The management of cancer-associated venous thromboembolism (VTE) is also likely 
to change in the upcoming years. DOACs will be first-line treatment because ongoing 
trials will probably reveal non-inferiority of DOACs as compared with standard treat-
ment with low-molecular-weight heparin (LMWH), where the oral administration of 
DOACs is more practical and patient-friendly. However, not all patients with a cancer-
associated VTE are candidates for DOAC treatment. DOACs have shown to be associated 
with more gastrointestinal and abnormal uterine bleeding than VKAs. This suggests that 
patients with mucosal tumour types might not benefit from DOAC treatment. Although 
a direct comparison is lacking, apixaban is thought to be associated with less major 
bleeding than other DOACs. While awaiting the results of the ongoing CARAVAGGIO 
study (ClinicalTrials.gov Identifier: NCT03045406), apixaban might become an attractive 
DOAC in this patient category. However, a head-to-head trial would be needed to detect 
differences between DOACs but it remains to be seen whether such a study will ever be 
performed. In addition, both DOAC and LMWH treatment are not indicated in patients 
with end-stage renal failure. In these patients, novel anticoagulation agents may be 
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of great value. It has been postulated that selective inhibition of intrinsic coagulation 
factors could provide antithrombotic benefits with low bleeding risk because this will 
keep the other pathways of coagulation intact for hemostasis. Consequently, factor XI 
inhibitors have emerged as promising new anticoagulants that may prove to be safer 
than VKAs or DOACs. The clinical potential of this anticoagulant strategy may represent 
an exciting new era in anticoagulation, including cancer-associated VTE.
As for the appropriate antithrombotic strategy after bioprosthetic aortic valve im-
plantation and mitral valve repair, future large randomized clinical trials will provide 
conclusive results about the optimal treatment to prevent arterial and venous throm-
botic complications. Although a high number of patients is needed to achieve sufficient 
power, the ideal study design for both surgical procedures would be to compare three 
treatment groups: aspirin, VKA and DOAC. Compared with VKA, aspirin and DOAC 
therapy will likely result in a lower bleeding and similar thrombotic risk. Subsequently, a 
risk prediction model needs to be developed to select patients who might benefit from 
either treatment strategies. DOACs might be preferable in patients who, for instance, 
are at high risk of developing atrial fibrillation postoperatively, whereas aspirin might be 
favoured in patients without any risk factors or in those with high bleeding risk. Notably, 
transcatheter aortic valve implantation (TAVI) and a MitraClip will compete with the sur-
gical gold standard. These catheter methods are currently limited to a high-risk patient 
population with severe valve disease but will likely be increasingly used. A TAVI may 
require a different antithrombotic approach than a surgical bioprosthetic aortic valve 
replacement because of a higher risk of valve thrombosis, which is associated with early 
valve degeneration. Consequently, ongoing trials comparing current treatment stan-
dard with dual antiplatelet therapy versus a DOAC and single antiplatelet therapy will 
possibly show a benefit of DOACs after a TAVI. The appropriate antithrombotic therapy 
following a MitraClip procedure should be evaluated according to the same study de-
sign of ongoing TAVI studies, where antiplatelet monotherapy will likely be sufficient to 
prevent thrombotic complications.
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Dit proefschrift is gericht op het evalueren en verbeteren van antitrombotische behan-
delstrategieën in patiënten die zich presenteren met een veneuze trombo-embolie (VTE) 
en die een hartklepoperatie moeten ondergaan om arteriële trombose te voorkomen. 
Daarnaast bespreekt dit proefschrift zich over de behandeling van dabigatran-gerela-
teerde majeure bloeding met idarucizumab. hoofdstuk 1 is een algemene introductie 
en overzicht van de beschreven studies in dit proefschrift.
deel 1: Veneuze trombo-embolie
hoofdstuk 2 beschrijft de resultaten van een systematische review en meta-analyse 
waarin het sterfterisico van een recidief VTE na het stoppen van antistollingsbehande-
ling is onderzocht in patiënten die zich initieel presenteerden met een spontane VTE. 
In totaal werden 8914 patiënten geïncludeerd in 24 studies van hoge kwaliteit. We 
observeerden een totaal sterfterisico van 0.13 (95%CI 0.036-0.25) per 100 persoonsjaren 
dat overeenkwam met een letaliteit van 2.0% (95%CI 0.69-3.8). Deze meta-analyse liet 
echter belangrijke heterogeniteit tussen de studies zien. Deze bevindingen verstrekken 
belangrijk informatie over het wel of niet verlengen van antistollingsbehandeling in 
patiënten met een spontane VTE. Huidige aanbevelingen van richtlijnen over het ver-
lengen van de antistollingsbehandeling bij een spontane VTE worden ondersteund als 
toekomstige observationele studies aantonen dat langdurige antistollingsbehandeling 
met direct orale anticoagulantia (DOACs) geassocieerd zijn met een lager fataal bloe-
dingsrisico dan 0.25% per jaar. Dit is de bovengrens van het 95% betrouwbaarheidsin-
terval van het jaarlijkse sterfterisico aan een recidief VTE.
De twee daaropvolgende hoofdstukken hebben betrekking op het stoppen van 
dagelijkse subcutane injecties met laag-moleculair-gewicht heparine (LMWH) in 
patiënten met een kanker-geassocieerde VTE. In hoofdstuk 3 werd het stoppen van 
LMWH therapie geëvalueerd in een periode van 180 dagen in 372 patiënten met een 
kanker-geassocieerde VTE. Deze studie toonde aan dat een op de vijf patiënten was 
gestopt, meestal door ondragelijke pijn bij de injectieplek. Bovendien hebben verschil-
lende LMWH samenstellingen mogelijk invloed op het risico om te stoppen. hoofdstuk 
4 liet zien dat de behandeling met enoxaparine geassocieerd is met een hoger risico 
om te stoppen dan de behandeling met nadroparine (hazard ratio 2.8, 95%CI 1.06-7.2). 
Deze bevindingen zijn relevant voor de keuze tussen verschillende LMWHs bij de be-
handeling van kanker-geassocieerde VTE. De orale inname van DOACs blijft echter een 
aantrekkelijk alternatief als deze inderdaad non-inferieur blijken te zijn aan LMWH.
deel 2: arteriële trombotische complicaties na hartklepoperaties
Na een hartklepoperatie hebben patiënten een verhoogd risico op het ontwikkelen 
van arteriële trombo-embolieën. Hoewel alle patiënten met mechanische kunstklep-
pen levenslange antistollingsbehandeling nodig hebben, is dit na een biologisch 
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aortaklepvervanging en mitralisklepreparatie nog steeds omstreden. In hoofdstuk 5, 
beschrijven wij het risico op trombo-embolische en bloedingscomplicaties in patiënten 
die gedurende een jaar werden behandeld met ofwel acenocoumarol of aspirine na een 
biologische aortaklepvervanging. In deze retrospectieve studie van 402 patiënten in 
drie Nederlandse ziekenhuizen was acenocoumarol geassocieerd met meer bloedings-
complicaties (risk ratio: 8.41, 95%CI 3.58–19.79) en een gelijk aantal trombo-embolieën 
(risk ratio: 1.2, 95%CI 0.47–3.02) als aspirine. Deze studie geeft aan dat aspirine wellicht 
de voorkeur zou moeten krijgen boven acenocoumarol voor deze indicatie. hoofdstuk 
6 gaat ook over het vergelijken van de trombo-embolische en bloedingscomplicaties 
tussen een behandeling met vitamine K antagonisten (VKA) en aspirine, maar in dit 
geval na een mitralisklepreparatie. In 469 patiënten werd geen verschil gevonden in 
de cumulatieve incidentie van een gecombineerd eindpunt van trombo-embolische 
en bloedingscomplicaties na 3 maanden (hazard ratio: 1.6, 95%CI 0.83-3.1). Bovendien 
waren het trombo-embolisch risico (hazard ratio: 0.82, 95%CI 0.16-4.2) en het bloedings-
risico (hazard ratio: 1.89, 95%CI 0.90-3.9) gelijk in beide behandelgroepen. Deze bevin-
dingen suggereren dat de antitrombotische behandeling na een mitralisklepreparatie 
geïndividualiseerd moet worden op basis van patiënt-specifieke eigenschappen, zoals 
(risicofactoren voor) atriumfibrilleren, therapietrouw en kwetsbaarheid.
deel 3: Idarucizumab als antidotum van dabigatran
Sinds enige tijd is het specifieke antidotum idarucizumab beschikbaar voor het acuut 
couperen van dabigatran in patiënten met een onbedwingbare of levensbedreigende 
bloeding, of in patiënten die een spoedinterventie moeten ondergaan. In hoofdstuk 
7 onderzochten wij adequaat gebruik van idarucizumab. In deze observationele multi-
center studie includeerden wij 88 patenten in 12 Nederlands ziekenhuizen: 53 patiënten 
die zich presenteerden met een bloeding en 35 patiënten die een spoedinterventie 
ondergingen. Wij observeerden onrechtmatig gebruik van idarucizumab in 28% van de 
patiënten. Ondanks het feit dat idarucizumab de prognose van patiënten in een acute 
setting kan verbeteren is er weinig bekend over hypersensitiviteit en interacties met 
andere medicijnen. Tevens heeft het mogelijk een negatieve impact op de kosten van 
de gezondheidszorg. In de groep patiënten met een bloeding bereikte twee-derde een 
effectieve hemostase na toediening van idarucizumab. Deze proportie is gelijk aan voor-
gaande studies die de effectiviteit van andere antidota hebben geëvalueerd. In overeen-
stemming met de grote RE-VERSE AD studie was het risico op trombo-embolische en 
bloedingscomplicaties 4.2%, en de sterfte 19% gedurende de 90 dagen dat patiënten 
gevolgd werden. Deze hoge mortaliteit onderstreept de slechte prognose van patiënten 
die antistolling gebruiken maar een bloeding krijgen of een spoedinterventie moeten 
ondergaan, zelfs als het antistollingseffect snel ongedaan kan worden gemaakt. hoofd-
stuk 8 was gericht om inzicht te geven in de effectiviteit en veiligheid van idarucizumab 
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in patiënten met majeure gastro-intestinale bloedingen tijdens behandeling met dabi-
gatran. Dit betrof een sub-analyse van 137 van de 301 patiënten die geïncludeerd waren 
in de bloedingsgroep van de originele RE-VERSE AD studie. Daarmee was dit de meest 
voorkomende bloedingslocatie. Idarucizumab toonde snelle en complete neutralisatie 
van dabigatran activiteit in 98% van de patiënten die bij binnenkomst in het ziekenhuis 
een verhoogde verdunde trombine tijd (dTT) hadden als teken van dabigatran activiteit, 
ongeacht de gastro-intestinale bloedingslocatie. Deze studie bevestigde dat idarucizu-
mab effectief is in het neutraliseren van dabigatran in patiënten die zich presenteren 
met een majeure gastro-intestinale bloeding.
Toekomstperspectief
In de nabije toekomst zullen directe orale anticoagulantia (DOACs) mogelijk niet 
alleen een belangrijke rol spelen bij veneuze trombose, maar ook in het voorkomen 
van arteriële trombose in patiënten met stabiel cardiovasculair vaatlijden. Momenteel 
wordt plaatjesaggregatieremming ingezet als secundaire cardiovasculaire preventie 
omdat antistolling met vitamine K antagonisten (VKAs) – alleen of in combinatie met 
plaatjesaggregatieremming – geassocieerd was met een hoger risico op bloedingen, 
inclusief intracraniële bloedingen. Een recente studie die de effectiviteit en veiligheid 
van DOACs heeft onderzocht in patiënten met cardiovasculair vaatlijden toonde een 
lager risico op arteriële trombotische complicaties bij een behandelcombinatie van een 
zeer lage dosis rivaroxaban en aspirine dan bij een behandeling met alleen aspirine (1). 
Echter, meer onderzoek is vereist om de waarde van deze behandeltherapie goed in 
te kunnen schatten. Andere plaatjesaggregatieremmers – vooral dubbele plaatjesag-
gregatieremming – hadden bij de studie betrokken moeten worden omdat ook deze 
effectief zijn in het voorkomen van trombotische complicaties. Het zou daarom zeer 
relevant zijn om de combinatie van rivaroxaban en aspirine te vergelijken met een P2Y12 
remmer (bijvoorbeeld ticagrelor) en de combinatie van een P2Y12 remmer en aspirine. 
Een dergelijke studie zal de veelbelovende resultaten van DOACs in het voorkomen van 
arteriële trombose mogelijk afzwakken.
De behandelstrategie van een kanker-geassocieerde veneuze trombo-embolie (VTE) 
zal de komende jaren veranderen. DOACs worden waarschijnlijk eerste keus behandeling 
gezien de huidige studies non-inferioriteit van DOACs ten opzichte van de standaardbe-
handeling met laag-moleculair-gewicht heparine (LMWH) suggereren, waarbij de orale 
inname van DOACs praktischer en patiëntvriendelijker is. Niet elke patiënt heeft echter 
baat bij een behandeling met een DOAC. DOACs zijn geassocieerd met een hoger risico 
op gastro-intestinale en abnormale uterine bloedingen dan VKAs. Dit suggereert dat 
DOACs mogelijk vermeden moeten worden in patiënten met mucosale tumoren. Hoewel 
een directe vergelijking ontbreekt, is apixaban mogelijk geassocieerd met minder ma-
jeure bloedingen dan andere DOACs. Of dit ook in de setting van kanker gerelateerde 
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trombose geldt moet worden afgewacht. Momenteel wordt de CARAVAGGIO studie (Cli-
nicalTrials.gov Identifier: NCT03045406), uitgevoerd, waarbij apixaban wordt vergeleken 
met dalteparine bij de behandeling van kanker-gerelateerde VTE. Echter, een rechtstreeks 
vergelijkende studie zal uitgevoerd moeten worden om verschillen tussen DOACs aan te 
tonen. Het blijft de vraag of een dergelijke studie ooit zal worden uitgevoerd. Tevens is 
een behandeling met DOAC en LMWH niet geïndiceerd in patiënten met eindstadium 
nierfalen. In deze patiënten kunnen nieuwe anticoagulantia een goede uitkomst bieden. 
Momenteel wordt verondersteld dat specifieke remming van de intrinsieke stollingscas-
cade een antitrombotisch voordeel zou kunnen opleveren met een lager een bloedingsri-
sico omdat andere onderdelen van de stollingscascade intact blijven voor het behouden 
van hemostase. Daarom wordt de werking van factor XI remmers onderzocht als veelbe-
lovende nieuwe antistollingsmiddelen die mogelijk veiliger zijn dan VKAs of DOACs. Het 
potentieel van deze antistollingsstrategie luidt mogelijk een nieuw tijdperk in van nieuwe 
antistolling strategieën, ook bij de behandeling van een kankergeassocieerde VTE.
Wat betreft de antitrombotische strategie na een biologische aortaklepvervanging 
en een mitralisklepreparatie zullen grote gerandomiseerde trials duidelijkheid moeten 
verschaffen over de optimale behandeling om arteriële en veneuze trombose te voor-
komen. Hoewel een groot aantal patiënten vereist is om goede conclusies te kunnen 
trekken, zullen na beide procedures idealiter drie behandelgroepen moeten worden 
vergeleken: aspirine, VKA en DOAC. In vergelijking met de VKA, resulteren aspirine en 
DOACs waarschijnlijk in een lager bloedings- en gelijk trombo-embolisch risico. Ver-
volgens zal een predictiemodel ontwikkeld moeten worden ontwikkeld die patiënten 
selecteert die baat hebben bij één van beide behandelstrategieën. Een DOAC geniet 
mogelijk de voorkeur in patiënten met een hoogrisico op het ontwikkelen van atrium-
fibrilleren, waar aspirine adequaat is in patiënten zonder risicofactoren of in diegenen 
met een hoog bloedingsrisico. Bovendien is het mogelijk dat de minder invasieve 
transkatheter aortaklepvervanging (TAVI) en MitraClip procedures in de plaats komen 
van de chirurgische behandeling. Deze transkatheter procedures worden momenteel 
alleen nog maar verricht in hoogrisico patiëntengroep met ernstige klepziekten, maar 
zullen naar verwachting toenemen in andere patiëntcategorieën. Een TAVI vereist 
mogelijk een andere antitrombotische strategie dan een chirurgische biologische 
aortaklepvervanging wegens een hoger risico op kleptrombose, dat geassocieerd 
is met vroegtijdige klepdegeneratie. Derhalve zullen lopende studies, die de huidige 
standaardbehandeling met dubbele plaatjesaggregatieremming vergelijkt met een 
DOAC en enkele plaatjesaggregatieremming, mogelijk een voordeel aantonen van 
een behandeling met DOACs. Het optimale antitrombotische beleid na een MitraClip 
procedure zal moeten worden geëvalueerd volgens eenzelfde onderzoeksopzet als 
de lopende TAVI studies, waarin plaatjesaggregatieremming waarschijnlijk voldoende 
beschermt tegen het optreden van trombose.
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